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ABSTRACT
Cardiovascular disease is responsible for the loss of one life every 38
seconds and accounts for 26.6 percent of all infants that die of congenital birth
defects. Adrenergic hormones are critically important regulators of
cardiovascular physiology in embryos and adults. They are key mediators of
stress responses and have profound stimulatory effects on cardiovascular
function, and dysregulation of adrenergic function has been associated with
many adverse cardiac conditions, including congenital malformations,
arrhythmias, ischemic heart disease, heart failure, and sudden cardiac death.
Despite intensive study, the specific roles these hormones play in the developing
heart is not well-understood. Further, there is little information available
regarding how these important hormones mediate stress responses in adult
females (before and after menopause) in comparison to males. My thesis thus
has two major foci: (1) What role(s) do catecholamines play in the embryonic
heart?, and (2) Do catecholamines differentially influence cardiac function in
aging male and female hearts?
Initially, we sought to uncover the roles of adrenergic hormones in the
embryonic heart by utilizing an adrenergic-deficient (Dbh-/-) mouse model. We
found that adrenergic hormones influence heart development by stimulating
expression of the gap junction protein, connexin 43, facilitating atrioventricular
conduction, and helping to maintain cardiac rhythm. As development
progresses, cardiac energy demands increase substantially, and oxidative
iii

phosphorylation becomes vital. Adrenergic hormones regulate metabolism in
adults, thus we hypothesized they may stimulate energy metabolism during the
embryonic/fetal transition period. We examined ATP, ADP, oxygen consumption
rate, and extracellular acidification rates and found these metabolic indices were
significantly decreased in Dbh-/- hearts compared to Dbh+/+ controls. We
employed transmission electron microscopy of embryonic cardiomyocytes and
found the mitochondria were significantly larger in Dbh-/- hearts compared to
controls, and had more branch points. Taken together, these results suggest
adrenergic hormones play a major role mediating the shift from predominantly
anaerobic to aerobic metabolism during the embryonic/fetal transition period.
Since there are known differential cardiac responses due to sex, age, and
menopause to stress, we used echocardiography to measure left ventricular (LV)
function in adult (9, 18 and 21 month) male and female mice (pre and
postmenopausal) in response to epinephrine, and immobilization stress to
investigate the roles of these factors. My results show 9-month premenopausal
female mice display significantly decreased LV responsiveness to epinephrine
compared to males, and an increased response to epinephrine due to age,
especially in the premenopausal females. Similar LV function was also observed
between postmenopausal females and males, and this pattern persisted after
immobilization stress. I also investigated anatomical differences in the
distribution of adrenergic cells within the heart comparing age, sex, and
menopausal status. Notably, the density of cells derived from an adrenergic
iv

lineage in the heart was significantly increased in postmenopausal mice
compared to age-matched males and cycling females. The selective reappearance of adrenergic cells in the heart following menopause may provide an
explanation for the differential stress responses observed in our system, and
could have important clinical ramifications for stress-induced cardiomyopathies.
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CHAPTER ONE: INTRODUCTION
Adrenergic hormones and embryonic electrophysiology
The mammalian cardiac conduction system is comprised of the SA and
AV nodes, bundle of His, and Purkinje fibers (Christoffels and Moorman, 2009;
Moorman et al., 1998). The electrical signal is propagated in the SAN and
travels to the AVN where there is a significant delay. The signal then travels to
the bundle of His, located in the interventricular septum, where it is then passed
to the interventricular Purkinje fibers to initiate ventricular muscular contractions
(Keith and Flack, 1907).
The mouse primitive embryonic heart begins to display contractions at
approximately embryonic (E)7.5 (~22 days in humans). This is considerably
earlier than sympathetic innervation of the heart is seen, E16-17 in rat
(Shigenobu et al., 1988). The adrenergic hormone synthesizing enzyme
phenylethanolamine-n-methyltransferase (PNMT) (Figure 1), however, was found
to be present as early as E9.5 in the rat heart (~E8.5 in mouse) (Ebert et al.,
1996). Similar findings of this and other catecholamine biosynthesis enzymes
(ie. tyrosine hydroxylase and dopamine β-hydroxylase) have been shown in the
chick and even human heart (Huang et al., 1996; Ignarro and Shideman, 1968a,
b).
The localization of these “Intrinsic Cardiac Adrenergic” (ICA) cells is
intriguing as they are found to colocalize with regions of the AV canal and the
dorsal venous valve cusp at rat E11.5 (Ebert et al., 1996). These regions of the
1

embryonic heart further develop into the AV node and SA node, respectively
(Viragh and Challice, 1977, 1980, 1982). These cells are seemingly transitory
and later at E16.5 (rat) large clusters where observed in the crest of the
interventricular septum, the sight of the bundle of His and Purkinje fibers (Ebert
et al., 1996). In addition, at E15.5 (mouse) co-staining was observed between
historical staining of adrenergic cells and Hyperpolarization-activated cyclic
nucleotide-modulated channel isoform 4 (HCN4) (Ebert et al., 2004) a protein
associated with pacemaker properties found in the SA node (Stieber et al.,
2003).
While there is strong evidence for colocalization of ICA cells with key
pacemaker and conduction regions of the heart few studies have investigated the
relationship between adrenergic hormones and the electrophysiology of the
embryonic heart and the necessity of these hormones for proper function of the
conduction system. Here we explore the roles of adrenergic hormones in the
development of the embryonic conduction system.

Adrenergic hormones and embryonic energy metabolism
The primary source of adenosine triphosphate (ATP) during fetal
development is commonly reported to be from glycolysis and lactate production,
with a ‘fetal-shift’ occurring at birth where the primary source of ATP production
‘shifts’ to oxidative phosphorylation in the mitochondria (Duncan, 2011; Madrazo
and Kelly, 2008; Makinde et al., 1998). A typical example of this notion from the
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literature is stated as follows (Duncan, 2011; Madrazo and Kelly, 2008):
‘…metabolic programming often is referred to as a ‘fetal’ shift because the
myocardium of the developing embryo relies mostly on glycolysis and lactate
metabolism for its ATP production’. It has been known for more than 40 years,
however, that mammalian hearts show an increase in the importance of oxidative
phosphorylation for ATP production during the embryonic development (Cox and
Gunberg, 1972; Ellington, 1987; Shepard et al., 1970). Additionally, there is
accumulating evidence from targeted genetic studies in mice showing embryonic
lethality due to disruption of genes associated with the mitochondria and/or
dysfunctional oxidative phosphorylation. Moreover, cardiovascular development
has been well studied using transgenic mice demonstrating embryonic lethality
occurring around the time of mitochondrial maturation during organogenesis
(Conway et al., 2003; Porter et al., 2011). Organogenesis begins around
embryonic day 8.0 (E8.0) in mice, which is equivalent to about day 17–19
(Carnegie Stage 8) in humans (O'Rahilly, 1979; Theiler, 1972).
Interestingly, this is approximately the stage of development when
increased embryonic lethality due to the genetic disruption of mitochondrial
associated genes occurs (Figure 2) thereby demonstrating that embryonic
mitochondrial function is indeed critical for embryonic and fetal development in
utero. In support of this genetic evidence, electron microscopy has shown an
obvious maturation of mitochondria and cristae development between E10–12 in
rat embryos (equivalent to E9.0–E10.0 in mice) (Shepard et al., 1998). Further,
3

the inhibition of glycolysis using the drug 2-deoxyglucose did not show a
decrease in E9.0 mouse ATP concentrations, indicating an alternative
mechanism of energy production (e.g. oxidative phosphorylation) (Hunter and
Tugman, 1995). Until recently, the study of oxidative phosphorylation and
mitochondrial maturation in utero had not been thoroughly investigated, but a
new mechanism for the induction of mitochondrial maturation was proposed
involving the closure of the mitochondrial permeability transition pore (mPTP)
beginning at E9.5 in mouse cardiomyocytes (Hom et al., 2011). The closure of
the mPTP led to increased oxidative phosphorylation and decreased ROS
production in the E9.5 mouse heart, and has thus been proposed as a key
mechanism in the maturation of mitochondrial function in the developing embryo
at a time when the embryo becomes dependent on aerobic metabolism (Hom et
al., 2011).
Here, my studies show a link between adrenergic-hormones and
mitochondrial functional maturation during embryogenesis. Adrenergic
stimulation is known to regulate metabolism in adult organs, including the heart
and liver, however, this is the first study to carefully examine adrenergic
regulation of embryonic energy metabolism in the developing embryonic heart.

Adrenergic hormones, stress, age and gender
The impacts of emotional stress on health have been generally recognized
since ancient times, but only in relatively recent years have scientists and
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clinicians started to gain an understanding of the pathophysiological mechanisms
linking emotional stress to specific dysfunctions within the cardiovascular system.
In contrast, biological manifestations of physical stress are much more
extensively characterized, and broadly include hypertension, ischemic heart
disease (including myocardial infarction and its consequences), myocarditis,
cardiomyopathies, heart failure, arrhythmias, and sudden cardiac death (Steptoe
and Kivimaki, 2012). While emotional stress may also contribute to these
conditions, the specific pathophysiologic manifestations of emotional stress are
only beginning to emerge.
Takotsubo Syndrome is a prototypical stress-induced cardiomyopathy.
The first clinical cases of this stress cardiomyopathy were reported in Japan in
1990 (H. Sato, 1990). Early reports described a transient hypokinesis or akinesis
in the apex of the LV in patients suffering from acute emotional stress (Bybee
and Prasad, 2008; Hurst et al., 2010; Tsuchihashi et al., 2001). The unusual
shape of the heart in these patients bore a striking resemblance to a Japanese
octopus trap, and hence, it was named “takotsubo”, meaning octopus trap in
Japanese (Dote et al., 1991; H. Sato, 1990; Tsuchihashi et al., 2001). Takotsubo
Syndrome is also referred to as “Broken Heart Syndrome” (due to the emotional
stress connection), “Ampulla Cardiomyopathy” (due to the peculiar shape of the
heart), or “Apical Ballooning Syndrome” (to describe one of the most pronounced
clinical features commonly observed in these patients) (Hurst et al., 2010).
Takotsubo Syndrome is also referred to as a “Stress-Induced Cardiomyopathy”
5

or more simply, “Stress Cardiomyopathy”. These terms have become essentially
interchangeable when describing this syndrome (Sharkey et al., 2011). For this
purpose, we will use the historical “Takotsubo Cardiomyopathy (TTC)”
designation as the prototype clinical form of stress-induced cardiomyopathies. It
is important to note, however, that stress induction for TTC need not be
exclusively emotional or psychological, but can also be precipitated by physical
stressors such as pharmacological challenge with adrenaline and other
adrenergic agonists (Abraham et al., 2009; Litvinov et al., 2009), complications
from other diseases (e.g., pheochromocytoma) (Marcovitz et al., 2010; Naderi et
al., 2012), physical trauma from injury or surgery, and a wide variety of other
physical stressors (Ennezat et al., 2005; Patel et al., 2013).
The common feature of both physical and psychological stress responses
in these contexts is elevated plasma catecholamines (Akashi et al., 2004; Ito et
al., 2003; Kume et al., 2008; Wittstein et al., 2005). Indeed, studies examining
plasma catecholamine concentrations in TTC patients have shown high levels of
circulating catecholamines compared to those from control groups (Shao et al.,
2013a; Wittstein et al., 2005). The fact that exogenously administered
catecholamines can induce TTC-like symptoms in patients and animal models
further supports adrenergic mediation of this syndrome (Abraham et al., 2009;
Izumi et al., 2009; Shao et al., 2013a; Shao et al., 2013b). TTC symptoms have
also been reported in some patients with pheochromocytoma, which results in
abnormally high concentrations of circulating endogenous catecholamines
6

secreted from adrenal medullary tumors (Kim et al., 2010). TTC symptoms have
responded favorably to pharmacological intervention with beta-blockers in some
cases (Bybee and Prasad, 2008). Taken together, these observations strongly
implicate the major peripheral catecholamines, adrenaline and noradrenaline, as
key players in acute precipitation of TTC.
We hypothesize the pathogenesis of TTC is due (in part) to a local release
of catecholamines that overload adrenergic receptor signaling systems in specific
regions of the heart (Kume et al., 2008; Osuala et al., 2011), however the other
prevailing hypothesis include coronary microspasms and increased β-adrenergic
receptor densities (Figure 3). During stress, there is input from sympathetic
nerves as well as circulating catecholamines, but there are also
autocrine/paracrine actions of catecholamines from stores within the heart itself
(Armour et al., 1997; Ebert et al., 1996; Ebert and Taylor, 2006; Ebert and
Thompson, 2001; Elayan et al., 1990; Huang et al., 1996; Osuala et al., 2011;
Papka, 1974). As mentioned earlier, sympathetic nerve input is not uniform
throughout the LV. There is much greater nerve terminal density in the base
compared to mid or apical sections of the LV (Angelakos, 1965; Pierpont et al.,
1984). Kume et al, 2008 measured catecholamines from two locations
representing base (aortic root, Ao) and apex (coronary sinus, CS) in five
confirmed cases of TTC. In all five cases, concentrations of noradrenaline and
dopamine were elevated in CS compared to Ao, whereas adrenaline
concentrations were unchanged or slightly decreased. These results suggested
7

there may indeed be differential local catecholamine concentrations in apical and
basal regions of the left ventricular myocardium.
Another piece of evidence comes from recent studies in the mouse heart
showing cells marked by expression of the adrenaline biosynthetic enzyme,
phenylethanolamine n-methyltransferase (Pnmt), were found to be concentrated
on the left side of the adult heart (Osuala et al., 2011). More specifically, Pnmt+
cells were localized to swaths or finger-like projections into left ventricular
myocardium at the apex, mid, and basal regions (Osuala et al., 2011). These
data suggest there may be an anatomical substrate for regional catecholamine
production differences in the heart. Nearly 90% of Pnmt-derived cells were found
to be localized to the left side of the heart, which could, in theory, help to explain
why left ventricular function is selectively influenced in TTC. Moreover, the
regional variations within the LV could likewise help to explain how those areas
could be susceptible to local surges in catecholamines. It is also possible that
local presence of catecholamines in these regions during development may
influence the expression and functional sensitivities of adrenergic receptor
subtype distributions in the LV. Although this has not been explicitly
demonstrated in the heart, there are numerous studies showing that innervation
and adrenergic receptor expression is influenced by catecholamine exposure
(Clarke et al., 2010; Habecker et al., 1996; Lau et al., 1982).
Notably, many of the Pnmt-derived cells in the adult mouse heart appear
to be myocytes, though neuronal-like and immature embryonic-like Pnmt-derived
8

cells were also identified in these regions (Osuala et al., 2011). Clear examples
of striated myocardial cells marked with XGAL to denote Pnmt expression were
observed in the LV (Ebert et al., 2008; Osuala et al., 2011). These results
suggest there may be autocrine or paracrine actions of local catecholamines
from non-neuronal as well as neuronal sources. This idea is not new (Kimura et
al., 2012; Kloberg and Fritsche, 2002; Slavikova et al., 2003), but is often
overlooked in modern studies and textbooks. The classic work of Spurgeon et al.
(Spurgeon et al., 1974) showed that cardiac adrenaline concentrations remain
relatively high in the heart following surgical and chemical (6-hydroxydopamine,
6-OHDA) denervation, while noradrenaline concentrations were nearly
completely eradicated by these procedures. The authors concluded that cardiac
noradrenaline content was mostly neuronal while only ~50% of the adrenaline
content was neuronal. They hypothesized that cardiac adrenaline “is held in nonneuronal stores either in chromaffin cells, in the specialized cells themselves or
in cardiac analogs of chromaffin cells” (Spurgeon et al., 1974). There is ample
evidence for these from a wide variety of species (Abrahamsson et al., 1979;
Ellison and Hibbs, 1974; Forsgren et al., 1990; Padbury et al., 1981), including
humans (Dail and Palmer, 1973), suggesting their presence is highly conserved
and, therefore, likely critical for survival. It remains to be determined if these
cells truly play a significant role in TTC, but they certainly represent a potential
local source of adrenaline that could contribute to regional variations in
adrenergic stimulation within the LV.
9

To investigate this further I performed longitudinal high-resolution
echocardiography on male and female mice ranging from 9 to 21 months old.
Additionally, to test if menopausal status affects left ventricular heart function
ovarian follicle failure was induced and echocardiographs were repeated. The
effect of stress on heart function was tested by the injection of epinephrine and
immobilization. Lastly, adrenergic cell distributions patterns within the heart were
determined using X-gal staining.
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Figures

Figure 1 Catecholamine biosynthetic pathway
Catecholamine biosynthetic pathway with enzymes next to arrows.
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Figure 2 Timeline of attrition in genetic knock-out models that affect
mitochondrial function
‘ X’ represents a model of mitochondrial-associated lethality; vertical dashed lines
indicate timing of ‘embryonic-shift’ from anaerobic to aerobic metabolism. Please
note that arrows depicting timelines of activity for ‘glycolysis’ and ‘oxidative
phosphorylation’ are qualitative and mainly serve to indicate the relative
importance of glycolysis (and subsequent lactic acid formation through anaerobic
means) and oxidative phosphorylation in mitochondria for proper embryonic and
foetal development.
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Figure 3 Schematic illustrations of three distinctive models proposed to
explain TTC mechanisms.
1. Coronary Microspasms: In this model, stress-induced surges in
catecholamines trigger coronary microspasms, which then lead to decreased
blood flow and regional myocardial inactivity. 2. Increased β 2-Receptor Density:
This model proposes that β2-adrenergic receptors are more concentrated at the
apex compared to the base. High concentrations of adrenaline cause these
receptors to switch from Gs to Gi, which results in myocardial stunning in affected
regions that would appear as akinetic or hypokinetic sections of LV during
systole. 3. Increased Local Catecholamine Release: In this hypothesis,
adrenaline and/or noradrenaline are released locally in the apex, mid, and/or
basal regions of the LV from non-neuronal resident adrenergic cell populations
(depicted by the highlighted blue areas). This local release overstimulates
adrenergic receptors that are already near saturation from circulating adrenaline
and sympathetic nerves (NA). Abbreviations: HPA, Hypothalamic-PituitaryAdrenal (axis); A, adrenaline; NA, noradrenaline
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CHAPTER TWO:
ADRENERGIC DEFICIENCY LEADS TO IMPAIRED ELECTRICAL
CONDUCTION AND INCREASED ARRHYTHMIC POTENTIAL IN
THE EMBRYONIC MOUSE HEART
Abstract
The adrenergic hormones, epinephrine and norepinephrine, are produced
by cardiac cells in the pacemaking and conduction system, as well as other
portions of the heart during a critical period of embryonic development when
adrenergic action is essential for survival. The underlying mechanisms of
adrenergic action in the embryonic heart, however, are not well-understood. To
determine if adrenergic hormones play a critical role in the functional
development of the cardiac pacemaking and conduction system, we employed a
mouse model where adrenergic hormone production was blocked due to targeted
disruption of the dopamine -hydroxylase (Dbh) gene. Immunofluorescent
histochemical evaluation of the major gap junction protein, connexin 43, revealed
that its expression was substantially decreased in adrenergic-deficient (Dbh-/-)
mouse hearts relative to adrenergic-competent (Dbh+/+ and Dbh+/-) at embryonic
day 10.5 (E10.5), whereas pacemaker and structural protein staining appeared
similar. To evaluate cardiac electrical conduction in these hearts, we cultured
them on microelectrode arrays (8x8, 200 µm apart). Our results show a
significant slowing of atrioventricular conduction in adrenergic-deficient hearts
compared to controls (31.4 ± 6.4 vs. 15.4 ± 1.7 ms, respectively, p < 0.05). To
determine if the absence of adrenergic hormones affected heart rate and rhythm,
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mouse hearts from adrenergic-competent and deficient embryos were cultured
ex vivo at E10.5, and heart rates were measured before and after challenge with
the -adrenergic receptor agonist, isoproterenol (500 nM). On average, all
hearts showed increased heart rate responses following isoproterenol challenge,
but a significant (p < 0.05) 225% increase in the arrhythmic index (AI) was
observed only in adrenergic-deficient hearts. These results show that adrenergic
hormones may influence heart development by stimulating connexin 43
expression, facilitating atrioventricular conduction, and helping to maintain
cardiac rhythm during a critical phase of embryonic development.

Introduction
Mice that lack the ability to produce the adrenergic hormones,
norepinephrine (NE) and epinephrine (EPI), due to targeted disruption of the
dopamine -hydroxylase (Dbh) gene die at mid-gestation from apparent heart
failure (Thomas et al., 1995). Structural formation of the heart was not markedly
perturbed in the adrenergic-deficient embryos, though subtle abnormalities such
as dilated atria and disorganized ventricular myofibrils were observed in the
deficient group. In addition, blood pooling in major organs and slower in vivo
heart rates led to the conclusion that heart failure was the likely cause of death in
adrenergic-deficient embryos. The mechanism of action appears to be primarily
through -adrenergic receptor activation because isoproterenol (-agonist) but
not L-phenylephrine (-agonist) could rescue the adrenergic-deficient (Dbh-/-)
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mouse embryos when supplied via the maternal drinking water (Thomas and
Palmiter, 1998). Despite a relatively wide body of data on adrenergic
mechanisms in the adult heart, only rudimentary information exists regarding
adrenergic actions in the embryonic heart. A major gap in our current knowledge
is how embryonic activation of -adrenergic signaling specifically affects cardiac
function and embryonic survival at these critical formative stages of development.
Independent studies have shown that the heart itself is a source of
adrenergic hormones during early development (Ebert et al., 1996; Ebert and
Thompson, 2001; Huang et al., 1996). “Intrinsic Cardiac Adrenergic” (ICA) cells
appear in the heart at about the time that it first starts to beat (Ebert et al., 1996;
Huang et al., 1996). There is a transient clustering of ICA cells in regions of the
heart progressively associated with development of the cardiac pacemaking and
conduction system, including the pacemaker cells in the sinoatrial node, the
atrioventricular node, bundle of His, and Purkinje fibers (Ebert and Thompson,
2001). Some of these transient ICA cells appear to differentiate into cardiac
myocytes, including the specialized myocytes that serve as pacemaker cells in
the sinoatrial and atrioventricular nodes as well as extensive labeling of myocytes
throughout the ventricular conduction system (Ebert et al., 2004). These
observations have led us to hypothesize that NE and/or EPI play a critical role in
the embryonic development of the cardiac pacemaking and conduction system
(Ebert and Taylor, 2006).
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In the present study, we utilized the Dbh knockout mouse model to test
the hypothesis that NE and EPI play a critical role in the development of the
cardiac pacemaking and conduction systems. Our initial experiments evaluated
the in situ expression of a key pacemaker channel protein, the hyperpolarizationactivated cyclic nucleotide-modulated channel isoform 4 (Hcn4) (Stieber et al.,
2003), and a major gap junction protein responsible for fast ventricular
conduction, connexin 43 (Cx43) (van Veen et al., 2001), in adrenergic-competent
and deficient embryos. We then used microelectrode arrays (MEAs) to evaluate
electrical conduction, and videomicroscopy to examine heart rate and rhythm.
Our results indicate that while pacemaking activity appeared relatively unaffected
by the absence or presence of adrenergic hormones, electrical conduction was
impaired and susceptibility to arrhythmias was increased in adrenergic-deficient
hearts relative to controls.

Materials and Methods
Animals
The Dbh mouse strain and collection of embryos used in this study has been
described previously [25]. All animal procedures were performed in accordance
with NIH guidelines and were approved by the University of Central Florida
Animal Care and Use Committee. Most of our analyses were performed using
embryonic day 10.5 (E10.5) mouse embryos because E10.5 is the latest stage of
development when adrenergic-deficient embryos are still largely asymptomatic
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(Thomas et al., 1995). Since various secondary and other indirect effects of
adrenergic deficiency may occur as a consequence of heart failure at later
developmental stages, we confined our analyses to E10.5 and earlier stages in
an attempt to identify more direct mechanisms of adrenergic action in the
developing heart.

Immunofluorescence histochemistry
Dual immunofluorescent histochemical staining of hearts was performed
essentially as described previously (Ebert et al., 2004; Ebert and Thompson,
2001).

Ex vivo embryonic mouse heart cultures
E10.5 mouse hearts were isolated under aseptic conditions and cultured in
Dubelcco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum
(Hyclone Labs, Logan, UT) that had been charcoal-stripped to remove
catecholamine and steroid hormones (Natarajan et al., 2004). The media was
additionally supplemented with the following (final concentrations given): Dglucose (25 mM), sodium pyruvate (1 mM), penicillin G (100,000 U/L),
streptomycin (100 mg/L), β-mercaptoethanol (55 µM), l-glutamine (2 mM), and
1% 100x α-minimum nonessential amino acids (Ebert et al., 2007). Hearts were
cultured for 20-24 hours prior to any measurements of beating activity or
conduction properties.
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Microelectrode arrays (MEAs)
General MEA procedures were similar to those described previously (Pillekamp
et al., 2006), with the exceptions described here. Freshly isolated E10.5 hearts
were placed in the center of gelatin-coated 8x8 MEAs (#200/10iR-Ti,
Multichannel Systems, Reutlingen, Germany) with the flat ventral surface in
contact with electrodes (i.e., outflow tract projecting upward). A representative
video of an E10.5 spontaneously beating mouse heart on a MEA is shown in
Supplemental Video 3. Electrodes were 10 µm in diameter and 200 µm apart.
MEA analysis was performed using Clampfit v10.0.0.61 (Molecular Devices,
Sunnyvale, CA). The first depolarizing atrial electrode was considered the
sinoatrial region (SAR). The electrode with the largest depolarization in the
atrioventricular region was considered the atrioventricular junction (AVJ), and the
ventricular apex (APX) was identified both by location and bifurcation of impulse
propagation to the distal Purkinje fibers. Within the AVJ and APX regions,
adjacent electrodes depolarized usually near-simultaneously (<0.5 ms of each
other). Conduction time was measured between field potential minimums (FPmin)
(Halbach et al., 2003; Reppel et al., 2004).

Beating rate and rhythmicity measurements
Beating rate and rhythmicity measurements were performed as described
previously (Fink et al., 2009; Natarajan et al., 2004). Arrhythmic index (AI) was
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calculated as the median cycle length divided by the standard deviation (Fink et
al., 2009).

Statistics
Data are expressed as mean ± S.E.M. Student t-tests were performed to
compare means, with p < 0.05 required to reject the null hypothesis. No
significant differences were observed between wild-type (Dbh+/+) and
heterozygous (Dbh+/-) hearts at E10.5 in any examined parameter. Since there
was no significant difference between Dbh+/+ and Dbh+/- embryos (Thomas et al.,
1995), these two genotypes were combined into a single group referred to as
“adrenergic-competent." In contrast, homozygous knockout (Dbh-/-) mice were
designated as “adrenergic-deficient” due to their inability to produce NE or EPI
(Thomas et al., 1995).

Results
Since ICA cells have previously been identified in regions of the
developing heart associated with conduction and pacemaking function (Ebert et
al., 2004; Ebert and Thompson, 2001), we employed immunofluorescent
histochemical staining to evaluate a key pacemaking protein (Hcn4) and a major
gap junction protein (Cx43) important for the generation and propagation,
respectively, of electrical signaling in adrenergic-competent and deficient
embryonic hearts. As shown in Fig. 4, our results indicate that Cx43
immunofluorescent staining intensity in adrenergic-deficient hearts was
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substantially less than that observed in adrenergic-competent hearts (compare
red fluorescence in panels a and b). In this example, co-immunofluorescent
staining with Hcn4 showed similar distribution and intensity in both groups.
Higher magnification of the dual immunofluorescent staining in the SAN region is
shown in panels c and d. The arrowhead points to red Cx43-expressing cells
while the arrow indicates the Hcn4-expressing cells shown in green. Cx43expressing cells showed only marginal overlap with Hcn4-positive cells in the
SAN region, but were found in the adjacent atrial myocardial cells and extending
into the myocardium of the ventricle and outflow tract regions as well. This was
true for both adrenergic-competent and deficient E10.5 hearts, though the
intensity of the Cx43 staining in the deficient hearts was much less than that
seen in the competent hearts (compare panels c and d). This effect appeared to
be specific for Cx43 since anti-sarcomeric α-actinin staining in adjacent sections
showed similar intensity and distribution for both adrenergic-competent and
deficient hearts (compare red staining in panels e and f). Further, since the
same secondary antibody source and concentration were used for both
sarcomeric -actinin and Cx43, the relative decrease in Cx43 staining intensity
was probably not due to differential effects of the secondary antibody, but instead
likely reflects changes in Cx43 expression resulting from lack of adrenergic
stimulation.
We similarly analyzed other regions of the heart, and found that Cx43
immunofluorescent histochemical staining was also decreased in the
28

atrioventricular (A-V) area of adrenergic-deficient compared to adrenergiccompetent E10.5 embryos (Fig. 5). Low-magnification views of sarcomeric
αactinin immunofluorescent staining in adrenergic-competent and deficient
hearts (panels a and b) are provided to aid in orientation of the highermagnification views of Cx43 staining in these same sections, as shown in panels
c-f. When camera exposure times and image processing were optimized for
viewing of Cx43 in adrenergic-competent E10.5 mouse hearts, virtually no Cx43
staining was observed in the A-V junctional region of adrenergic-deficient hearts
using equivalent image acquisition and processing settings (compare panels c
and d, “dim”). Cx43 was not entirely absent from the A-V region of the
adrenergic-deficient hearts, however, as it can be seen when image processing
was adjusted to increase sensitivity. Equivalent processing of the images from
adrenergic-competent hearts led to overexposure of Cx43 immunofluorescent
staining, though the comparison with the deficient example under the same
conditions (“bright”) still clearly demonstrate the disparity of staining intensities
between adrenergic-competent and deficient E10.5 in the A-V regions (compare
panels e and f). These results further demonstrate that Cx43 expression is
selectively diminished in E10.5 adrenergic-deficient myocardium relative to that
found in adrenergic-competent hearts at this stage of development.
When examined one day earlier in development (E9.5), however, Cx43
staining intensity and distribution appeared similar in adrenergic-competent and
deficient mouse hearts (Fig. 6). Hcn4 immunostaining was also similar between
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these groups at E9.5 (compare panels a and b). Comparative views of Cx43 are
shown at low (panels c and d) and high (panels e and f) magnification. These
results demonstrate that the Cx43 immunofluorescent staining is not inherently
diminished in adrenergic-deficient hearts throughout development, suggesting
that decreased Cx43 expression occurs after E9.5.
To determine if the electrical properties of the developing embryonic heart
were altered as a result of adrenergic-deficiency, we cultured isolated E10.5
adrenergic-competent and deficient hearts on MEAs and measured extracellular
field potentials from different regions of the heart. These included the sinoatrial
region (SAR) near the SAN (sinoatrial node), the interchamber atrioventricular
junction region (AVJ), and ventricular apex (APX), as illustrated in Fig. 7.
Representative field potential traces from adrenergic-competent and deficient
hearts are shown from simultaneous MEA recordings at the SAR and APX
electrodes, indicating a general lengthening of the conduction time from SAR to
APX in deficient hearts. MEA measurements were thus obtained for a series of
these ex vivo embryonic heart preparations, and the combined results are
summarized in Table 1, where it can be seen that the atrioventricular conduction
time (AVJ-APX), which includes transmission time through the AVJ, was roughly
twice the duration in adrenergic-deficient hearts compared with competent
control hearts (31±6 vs. 15±2 ms, respectively, n=5/6, p < 0.05). In contrast,
atrial conduction times (SAR-AVJ) were not significantly altered between the
groups. The adrenergic-deficient hearts displayed slightly slower intrinsic heart
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rates and longer SAR-APX conduction times than adrenergic-competent controls
on average, but these differences were not significant. These data suggest that
there was a selective slowing of atrioventricular conduction velocity in
adrenergic-deficient E10.5 hearts whereas atrial conduction and average beating
rates were not significantly altered under these conditions.
To determine if adrenergic-deficient embryonic mouse hearts show
increased susceptibility to arrhythmia, we cultured adrenergic-deficient and
adrenergic-competent hearts ex vivo following isolation at E9.5 and E10.5. Heart
rate and rhythmicity were measured at baseline and after challenge with the adrenergic receptor agonist, isoproterenol (500 nM). This challenge resulted in
consistent 30-40% increase in heart rates for all groups within 2 minutes after
drug application (Fig. 8a). Baseline and isoproterenol-induced heart rates were
not significantly different between adrenergic-deficient and competent hearts at
either E9.5 or E10.5 (Supplemental Table). Arrhythmic index (AI) was used to
measure the rhythmicity of these isolated hearts before and after isoproterenol
treatment as previously reported and described in the Materials and Methods
section [9]. A significant (p < 0.05) 225% increase in AI from the adrenergicdeficient E10.5 mouse hearts was observed following the isoproterenol challenge
(Fig. 8b). Representative examples of adrenergic-competent (rhythmic beating)
and adrenergic-deficient (arrhythmic beating) hearts are provided in
Supplemental Videos 1 and 2, respectively. Relatively small non-significant (p >
0.05) increases in AI (< 50%) were observed for adrenergic-competent hearts at
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E10.5, and no significant differences were observed in AI for either group at E9.5
(Fig. 8b). These results demonstrate that by E10.5, adrenergic-deficient mouse
hearts were significantly more arrhythmic compared with adrenergic-competent
controls following acute challenge with isoproterenol.

Discussion
In the present study, we showed that adrenergic deficiency during
embryonic development leads to increased susceptibility for cardiac arrhythmias,
slowed atrioventricular conduction, and decreased expression of the major
cardiac gap junction protein, Cx43. We also showed that sarcomeric -actinin
and Hcn4 expression patterns and intensities were similar in adrenergiccompetent and deficient hearts, thereby suggesting that myocardial and
pacemaker cell development are grossly normal in the absence of NE and EPI.
These results are supported by the finding that heart rates were not significantly
different in adrenergic-competent and deficient hearts. Taken together, these
results suggest that adrenergic hormones are not required for the development of
cardiac pacemaking activity through E10.5 in the mouse, but instead function to
stimulate Cx43 expression, facilitate atrioventricular conduction, and maintain
cardiac rhythmicity.
Initially, we aimed to examine protein staining intensity and distribution
patterns for Cx43 and Hcn4 to determine if these are altered in adrenergicdeficient embryonic hearts around the time of their demise. Cx43 staining was

32

less intense relative to that for sarcomeric -actinin and Hcn4 in adrenergicdeficient hearts compared with competent controls at E10.5. Our coimmunofluorescent histochemical staining data show that was not true one day
earlier at E9.5, where Cx43 expression was not diminished in adrenergicdeficient hearts relative to controls or to sarcomeric -actinin and Hcn4 staining.
These results indicate that Cx43 appears to develop normally through E9.5 in
adrenergic-deficient hearts, but that it either becomes down-regulated or fails to
be up-regulated due to the lack of NE and EPI, such that by E10.5, Cx43
expression was substantially lower in adrenergic-deficient hearts than in controls.
The pattern of Cx43 distribution, which remained diffuse and spotty, as has been
seen in other studies at these early developmental stages (Coppen et al., 2003;
Delorme et al., 1997; Fromaget et al., 1992; Peters et al., 1994), did not appear
to be altered in adrenergic-deficient mouse hearts, but the intensity of the
staining for Cx43 was substantially reduced compared with equivalent staining in
the control group.
Disruption of both Cx43 alleles (Cx43-/-) results in lethality at birth due to
cardiac malformation resulting from swelling and blockage of the right outflow
tract (Reaume et al., 1995). Surprisingly, cardiac conduction speeds were not
altered much at E12.5, the earliest developmental timepoint measured in Cx43-/hearts, though significant slowing became apparent by E15.5 and continued to
lengthen thereafter (Vaidya et al., 2001). Cardiac-restricted Cx43 knockouts
survive through birth, but die within the first two months of life from sudden
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cardiac death due to severe arrhythmias (Gutstein et al., 2001). Ventricular
conduction velocity was also markedly slowed in these animals. Additionally,
cultured embryonic myocytes derived from Cx43-/- hearts show dramatic
reductions in conduction speeds relative to Cx43+/- or Cx43+/+ controls
(Beauchamp et al., 2004). Thus, it is well-established that Cx43 plays a critical
role in mediating ventricular conduction through the fetal and early postnatal
periods. At earlier stages of embryonic development, it may be less critical as
compensation by Cx40 and Cx45 appear to help ameliorate conduction slowing
due to the absence of Cx43 (Vaidya et al., 2001), though there is evidence
suggesting that expression and activity may also be compromised in Cx43-/myocytes (Beauchamp et al., 2004; Johnson et al., 2002; Kirchhoff et al., 2000;
Xie et al., 2009). These caveats notwithstanding, lowered Cx43 expression in
adrenergic-deficient hearts could contribute to the observed slowing of
atrioventricular conduction. We expect to find additional targets of embryonic
adrenergic hormone action in the developing heart that will also likely contribute
to the slowed atrioventricular conduction and arrhythmogenic phenotype of
adrenergic-deficient mice.
Microelectrode arrays provided ex vivo heart rate and conduction analysis
of cultured adrenergic-competent and deficient embryonic hearts. One of the
limitations of the MEA analysis, however, was the relatively large electrodeelectrode distance (200 µm) compared to the small heart (~600 x ~800 µm). In
addition, the 2-dimensional MEA surface could only examine the ventral plane of
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the 3-dimensional heart. Despite these limitations, the data from the MEA
experiments demonstrated that atrioventricular conduction was slower in
adrenergic-deficient hearts. Of note, it has been reported that E10.5 is
approximately the stage of development in the mouse when ventricular
conduction transitions from a base-to-apex to an apex-to-base pattern of
excitation (Rentschler et al., 2002). It is therefore conceivable that adrenergic
hormones could play a role in mediating this transition in the developing heart.
Future experiments are needed to further explore the underlying molecular
mechanisms that mediate adrenergic influence on the development of
atrioventricular conduction.
Failure to complete this transition in a coordinated and timely manner
could have critical consequences for heart development and embryonic survival if
the myocardium becomes more susceptible to arrhythmogenesis. Adrenergiccompetent and deficient embryonic hearts did not show a difference in basal AI;
however, isoproterenol challenge did induce significantly increased AI in
adrenergic-deficient E10.5 hearts compared to controls. This indicates that in ex
vivo cultured conditions adrenergic hormones help maintain a balance of
rhythmic beating even after increased stimulation. Other mechanisms of adrenergic regulation, such as synchronization of intracellular Ca2+ oscillations
(Song et al., 2001), may also impact arrhythmia susceptibility in adrenergicdeficient hearts. Consequently, we cannot say for certain if the altered Cx43
expression and slowed atrioventricular conduction observed in adrenergic35

deficient hearts were contributory to the increased propensity for arrhythmias. If
such arrhythmias are triggered in vivo, they could certainly contribute to the
observed heart failure and fetal lethality in adrenergic-deficient mice, but further
study is required to make that determination.
In summary, we have shown that adrenergic deficiency led to decreased
Cx43 in E10.5 but not E9.5 mouse hearts. We have also for the first time shown
that atrioventricular conduction is significantly slower in adrenergic-deficient
hearts, and that arrhythmic activity was significantly induced in adrenergicdeficient hearts compared with adrenergic-competent controls. In contrast,
pacemaking cell development and gross cardiac structural development of the
early muscle chambers appear relatively normal in adrenergic-deficient embryos
through E10.5. Thus, our data do not support the hypothesis that adrenergic
hormones are critical for development of cardiac pacemaking, but they are
supportive of a role for adrenergic hormones in stimulating Cx43 expression,
facilitating atrioventricular conduction, and helping to maintain cardiac rhythm
during a critical early period of embryonic heart development.
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Tables
Table 1 Summary of MEA data from E10.5 mouse hearts.

Heart Rate (bmp)
Conduction Time: SAR-APX (ms)
Conduction Time: SAR-AVJ (ms)
Conduction Time: AVJ-APX (ms)

AdrenergicCompetent
148.6 ± 10.7
(11)
52.1 ± 4.0
(11)
33.8 ± 3.0
(6)
15.4 ± 1.7
(6)

*, p < 0.05
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AdrenergicDeficient
120.7 ± 6.7
(6)
64.8 ± 9.1
(6)
29.8 ± 4.8
(5)
31.4 ± 6.4 *
(5)

Table 2 Values for heart rate and arrhythmic index responses to
isoproterenol challenge in adrenergic-competent and deficient embryonic
mouse hearts isolated at E9.5 (a) and E10.5 (b).
a. Heart rate and arrhythmic index at baseline and in response to isoproterenol in
E9.5 adrenergic-competent and deficient embryos.

Adrenergic-competent (5)

Adrenergic-deficient (4)

Baseline

Isoproterenol

Baseline

Isoproterenol

Heart Rate (bpm)

119.6 ± 9.8

160.0 ± 14.6

137.3 ± 7.8

177.5 ± 6.6

Arrhythmic Index

0.03 ± 0.01

0.02 ± 0.001

0.04 ± 0.03

0.02 ± 0.003

b. Heart rate and arrhythmic index at baseline and in response to isoproterenol in
E10.5 adrenergic-competent and deficient embryos.

Adrenergic-competent (17)

Adrenergic-deficient (5)

Baseline

Isoproterenol

Baseline

Isoproterenol

Heart Rate (bpm)

112.7 ±
10.1

159.6 ± 12.6

148.8 ±
15.2

206.4 ± 16.1

Arrhythmic Index

0.06 ± 0.01

0.05 ± 0.01

0.04 ± 0.02

0.08 ± 0.02
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Figures

Figure 4 Immunofluorescent histochemical evaluation of Cx43 relative to
Hcn4 and sarcomeric α-actinin expression in adrenergic-competent and
deficient E10.5 mouse hearts.
(a,b) Low-magnification (Lo-Mag, 20X objective) views of adrenergic-competent
and deficient mouse hearts, respectively, for Cx43 (red) and Hcn4 (green). Colocalized areas appear yellow. Scale bar for panels a-b, 0.1 mm. (c,d) Highmagnification (Hi-Mag, 60X objective) views of the corresponding SAN regions
(arrows) depicted in panels a and b, respectively, for adrenergic-competent and
deficient hearts stained for Cx43 and Hcn4. (e,f) Hi-Mag view of an adjacent
section co-stained for sarcomeric α-actinin (red) and Hcn4 (green) in adrenergiccompetent and deficient hearts. Arrow indicates Hcn4 staining (a-f), and
arrowhead indicates either Cx43 (a-d) or α-actinin (e,f) in approximately
equivalent regions of each heart. Scale bar for panels c-f, 25 µm.
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Figure 5 Immunofluorescent histochemical evaluation of Cx43 expression
in the A-V junction region of adrenergic-competent and deficient E10.5
mouse hearts.
(a, b) Low magnification (10X) objective of adrenergic-competent and deficient
heart sections stained for sarcomeric α-actinin. Scale bar for a-b 200 µm. (c,d)
Cx43 staining in the A-V junction region when pixel levels are optimized for
staining in the adrenergic-competent specimens (“dim”). (e, f) Same image as in
panels c and d, respectively but shown under “bright” conditions to optimize for
Cx43 appearance in the adrenergic-deficient specimens. Scale bar for c-f, 50
µm.

40

Figure 6 Immunofluorescent histochemical evaluation of Cx43 and Hcn4
expression in adrenergic-competent and deficient E9.5 mouse hearts.
(a,b) Hcn4 (green) staining (arrows) in adrenergic-competent and deficient
hearts, respectively. (c,d) Cx43 (red) staining (arrow) in adrenergic-competent
and deficient hearts, respectively. Scale bar for a-d, 50 µm. (e,f) Expanded
view of the Cx43 (boxed insets from panels c and d) in adrenergic-competent
and deficient hearts, respectively. Scale bar for e-f, 25 m.
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Figure 7 Illustrative conduction paths and representative field potential
traces from adrenergic-competent and deficient E10.5 mouse hearts
cultured ex vivo on MEAs.
(a) Representative heart shown without anchoring grid for visual clarity. Circle
indicates first electrode to depolarize in the sinoatrial region (SAR). Boxes
indicate electrodes depolarizing near-simultaneously (within 0.5 ms of each
other) in the atrioventricular junction region (AVJ) and ventricular apex (APX).
Arrows display overall evaluated conduction paths. (b,c) Representative field
potential recordings were aligned and compared from the SAR and APX regions
of adrenergic-competent and deficient hearts, respectively. Vertical dashed lines
were drawn to show how conduction times were measured from the FPmin (see
Materials and Methods for more details on how these measurements were
performed) [9]. Cumulative data from several experiments is shown in Table 1.
Figure contributed courtesy of Dr. David Taylor.
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Figure 8 Heart rate and arrhythmic index responses to isoproterenol
challenge in adrenergic-competent (black columns) and adrenergicdeficient (white columns) embryonic mouse hearts isolated at E9.5 and
E10.5.
(a) Percent change in heart rates following acute (2-min) challenge with 0.5 M
isoproterenol. (b) Percent change in arrhythmic index (AI) in response to acute
isoproterenol (0.5 M) challenge in adrenergic-competent and deficient
embryonic mouse hearts. *, p < 0.05 relative to control adrenergic-competent
E10.5 hearts.
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CHAPTER THREE:
IMPAIRED CARDIAC ENERGY METABOLISM IN EMBRYOS
LACKING ADRENERGIC STIMULATION
Abstract
We hypothesize that adrenergic hormones play a vital role in development
by providing critical stimulation of energy metabolism during the embryonic/fetal
transition period. To test this hypothesis, we examined ATP and ADP
concentrations in mouse embryos lacking the ability to produce the adrenergic
hormones, norepinephrine and epinephrine, due to targeted disruption of the
essential dopamine -hydroxylase (Dbh) gene. Our results show that embryonic
ATP concentrations decreased dramatically while ADP concentrations rose such
that the ATP/ADP ratio in the adrenergic-deficient group was nearly 50-fold less
than that found in littermate controls by embryonic day 11.5. We also found that
extracellular acidification and oxygen consumption rates were significantly
decreased, and mitochondria were drastically larger and more branched in
adrenergic-deficient hearts. Metabolic deficiencies in Dbh-/- embryos were
prevented by administration of the β-adrenergic agonist, isoproterenol. These
data demonstrate that adrenergic hormones stimulate cardiac energy metabolism
during a critical period of embryonic development.
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Introduction
The adrenergic hormones, epinephrine (EPI) and norepinephrine (NE),
are key mediators of stress responses and sympathetic nervous system activities
in adult mammals. NE, in particular, is also essential for embryonic
development. Targeted disruption of the gene dopamine β-hydroxylase (Dbh),
which codes for the enzyme that converts dopamine into NE, led to a loss of NE
and EPI, and embryonic lethality due to heart failure in mice (Thomas et al.,
1995). In contrast, disruption of the subsequent enzymatic step catalyzed by
phenylethanolamine n-methyltransferase (Pnmt) led to the loss of EPI without
concomitant developmental phenotypes (Ebert et al., 2004). Thus, while EPI
may contribute to adrenergic activity in the embryo, NE is clearly of critical
importance for heart development.
How NE influences heart development in utero is not fully understood. In
Dbh-/- embryos signs of cardiac distress begin to appear on embryonic day 10.5
(E10.5), and approximately 50% of the Dbh-/- embryos die by E11.5 (Thomas et
al., 1995). Remarkably, the heart appears to develop and function normally up to
this point, but then deteriorates rapidly into heart failure within 24h of the first
symptoms, which include sluggish cardiac contractions, arrhythmia, and
asynchrony as observed via echocardiography in utero (Osuala et al., 2012).
Recent work has shown that Dbh-/- hearts display significantly delayed
conduction speed across the atrioventricular junction relative to age-matched
littermate controls (Baker et al., 2012). These results suggest important
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adrenergic influences on the development of cardiac structure and function, but
do not fully explain how NE affects them.
At these early embryonic stages of development, there is no sympathetic
innervation of the heart, and the adrenal glands have not yet formed. Instead,
NE is produced in the embryonic heart itself, as well as outside of the heart in
primordial sympathetic ganglia and brainstem neurons (Ebert et al., 1996; Ebert
et al., 2004; Ebert and Thompson, 2001). With respect to heart function, NE
appears to be acting primarily through β-adrenergic receptors since Dbh-/embryos could be rescued by providing the β-agonist, isoproterenol, in the
maternal drinking water, whereas the α-agonist, l-phenylephrine, was ineffective
at rescuing the heart failure and lethality (Thomas and Palmiter, 1998). These
results established that NE stimulates cardiovascular functions during the early
embryonic period primarily through β-adrenergic receptors. But what are the
important downstream pathways and targets affected by β-adrenergic receptor
stimulation in the embryonic heart?
To gain insight about adrenergic actions in cardiac development, we
recently performed a genome-wide expression screen of Dbh-/- and Dbh+/+
embryonic hearts. A key finding from this screen demonstrated the largest
category of differentially expressed genes (~31% of total) were those involved in
metabolism (Osuala et al., 2012). In adult mammals, adrenergic hormones are
known to have profound and widespread influences on metabolism. In the liver,
for example, β-adrenergic stimulation inhibits glycolysis, promotes
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gluconeogenesis, and stimulates breakdown of glycogen (Berthet et al., 1957;
Sutherland and Wosilait, 1955). In cardiac and skeletal muscle, glycolysis and
oxidative phosphorylation (OXPHOS) are increased in response to β-adrenergic
stimulation to produce more available energy during stress. Free fatty acids are
released from adipose tissue, and these serve as the primary fuel source for
cardiac metabolism in adult mammals, but prior to birth the heart principally uses
carbohydrates (Bing et al., 1954; Carlsten et al., 1961; Cox and Gunberg, 1972;
Ellington, 1987; Gordon and Cherkes, 1956; Neely and Morgan, 1974; Shepard
et al., 1970). The shift from carbohydrate to lipid metabolism in the heart occurs
shortly after birth and is often referred to as the “fetal-shift” in cardiac metabolism
(Duncan, 2011; Madrazo and Kelly, 2008; Makinde et al., 1998). Surprisingly
little, however, is known regarding adrenergic influences on cardiac metabolism
during the embryonic period.
There is compelling evidence indicating that aerobic metabolism in the
mitochondria becomes increasingly important as the heart transitions from
embryonic to fetal stages of development. For example, genetic mutations that
decrease or disrupt OXPHOS often result in heart failure and embryonic lethality
(Humble et al., 2013; Larsson et al., 1998; Li et al., 2000). Furthermore,
mutations that disrupt mitochondrial structure and function also interfered with
cardiomyocyte differentiation and development(Chen et al., 2003; Chen et al.,
2011; Davies et al., 2007; Wakabayashi et al., 2009), and many of these
ultimately succumbed to heart failure and embryonic lethality. Thus, there
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appears to be an “embryonic-shift” from primarily anaerobic to aerobic metabolic
mechanisms in the heart during the embryonic-fetal transition period of
development (Baker and Ebert, 2013).
We hypothesize that adrenergic hormones play a critical role in facilitating
the metabolic shift towards aerobic oxidative phosphorylation in cardiac
mitochondria during embryonic development. Here, we test this hypothesis by
examining metabolic profiles of ATP, ADP, and ATP/ADP ratios in Dbh-/- and
control embryos. In parallel, we also examine other metabolic indices, including
cardiac oxygen consumption rate (OCR) and extracellular acidification rate
(ECAR) as estimators of aerobic and anaerobic metabolism, respectively. In
addition, we performed detailed ultrastructural analysis of mitochondria in
adrenergic-deficient and control hearts. As described in the next section, our
results show that both anaerobic and aerobic metabolism are compromised in
Dbh-/- hearts.

Materials and Methods
Mice
All procedures and handling of mice were conducted in accordance with The
University of Central Florida Institutional Animal Care and Use Committees. The
Dbh mouse strain was kindly provided by Dr. Richard Palmiter (University of
Washington, Seattle, WA) (Thomas et al., 1995) and maintained as previously
described (Baker et al., 2012; Osuala et al., 2012). Timed pregnancies were
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determined by the presence of a vaginal plug (denoted as E0.5) and further
confirmed by high-resolution ultrasound (Vevo 2100 instrument with 40 MHz
transducer; Visualsonics, Inc.) at E8.5. For isoproterenol rescue, maternal
drinking water was supplemented with 0.02 mg/ml isoproterenol and 2.0 mg/ml
vitamin C beginning at E8.5, as previously described (Thomas and Palmiter,
1998).

Reagents
Chemical reagents were purchased from Sigma-Aldrich, St. Louis, MO, unless
otherwise noted. Electron microscopy grade reagents for TEM were purchased
from Electron Microscopy Sciences, Hatfield, PA. Cell culture reagents were
purchased from Invitrogen, Grand Island, NY.

Embryonic tissue collections
All embryos used in this study appeared to be healthy and viable at the time of
isolation as judged by their size (crown-rump lengths), color, texture,
morphology, and overall appearance. Microscopic examination confirmed a
beating heart and bright red blood coursing through the embryonic circulation.
Unhealthy and dead embryos were discarded. From the living specimens
collected, no apparent differences were observed between adrenergic-deficient
and control embryos based on these gross examinations at the time of isolation.
Upon isolation, the heads were removed and used for genotyping. For enzyme
assays, trunks were flash-frozen in liquid nitrogen and stored at -80ºC. For some
52

experiments, E10.5 and E11.5 mouse hearts were isolated under aseptic
conditions and cultured in DMEM containing 10% fetal bovine serum (Hyclone
Labs) that had been charcoal-stripped to remove catecholamine and steroid
hormones (Natarajan et al., 2004). The media was additionally supplemented
with penicillin G (100,000 U/L) and streptomycin (100 mg/L). Hearts were
cultured for 24 hours prior to any measurements of oxygen consumption or
extracellular acidification rates.

ATP and ADP measurements
ATP and ADP measurements were performed with an Aposensor™ ATP/ADP
Ratio Bioluminescence Assay Kit (Biovision) as per manufacturer’s instructions.
Briefly, embryonic tissue was homogenized in 6% trichloroacetic acid (TCA) for 1
min then centrifuged at 6,000 g for 5 min at 4ºC. The supernatant was then
removed, and TCA was neutralized with tris-acetate as previously described
(Cosen-Binker et al., 2006). ATP measurements were performed with ATPlite™
Bioluminescence Assay (Perkin Elmer) as instructed by the manufacturers’
protocol. Standard curves were generated with known concentrations of ATP.
Luminescence was detected in an Envision Multilabel plate reader (Perkin
Elmer), and ATP measurements were normalized to total protein concentrations.

Lactate measurements
Embryos were homogenized in 8% perchloric acid for 1 min then centrifuged at
6,000 g for 4 min. Absorbance readings at 340 nm before and after addition of L53

lactate dehydrogenase was performed as described (Bergmeyer, 1974). The
supernatants for lactate measurements were combined with NAD solution (2.5 M
NAD, 0.2 M Glycine buffer, and 100 µL ≥500 units/mg protein L-lactate
dehydrogenase from bovine heart). Increase in absorbance at 340 nm was
compared to a standard curve of known lactate concentrations. Lactate
measurements were normalized to total protein concentrations.

Glucose measurements
Glucose was measured in triplicate using a WaveSense Presto blood glucose
monitoring system and compared to a standard curve of known D-glucose
concentrations.

Oxygen consumption rate and Extracellular acidification rate measurements
Hearts were isolated and cultured, as described above, in Seahorse Biosciences
XF24 Islet Capture Microplate with mesh grids placed on top of the specimen to
prevent it from floating and from probe interference. After 24 hrs culture media
was removed and replaced with serum free Seahorse XF Assay media and basal
oxygen consumption and extracellular acidification rates were simultaneously
measured with a Seahorse XFe system (Seahorse Biosciences) at 10-min
intervals over a period of 2 hrs. Rotenone (0.5 µM) and antimycin A (2 µM) were
added through separate injection ports (Zhang et al., 2012).
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Transmission Electron Microscopy
Experiments were performed as previously described (Song et al., 2011). Briefly,
isolated embryonic hearts were placed in Karnovsky’s fixative (2%
paraformaldehyde, 2.5% glutaraldehyde and 0.1 M sodium cacodylate) for 1
hour. Samples were then rinsed in 0.1 M sodium cacodylate with 3 µM CaCl2
and post-fixed in a 1% osmium tetroxide, 0.8% potassium ferrocyanide and 3 µM
CaCl2 solution. Samples were en bloc stained with 2% uranyl acetate and
dehydrated in graded ethanol solutions. Samples were embedded in Durcupan,
and thin sections were cut at 80nm using a Leica UTC Ultramicrotome and
diamond knife, and then mounted on copper grids. Thin sections were stained
with routine TEM double stain: Four minutes in 4% Uranyl Acetate. Four
minutes in Reynolds Lead Citrate. Thin Sections were examined using an FEI
268D TEM at 50Kv, and digital images recorded using an AMT XR-60 digital
camera. Mitochondrial morphometric analyses were performed with ImageJ
software (NIH).

JC-1 dye
Myocytes were isolated and cultured on coverglass (for microscopy) or 48-well
plates (for flow cytometry) as described previously (Maltsev et al., 1994).
Cardiomyocytes were cultured for 48 hours before staining with 5 µg/mL JC-1
dye (Invitrogen) for 20 min. Dye was washed with PBS and samples were either
viewed using a Perkin Elmer Spinning Disk confocal microscope or quantified
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using a BDFacs Canto flow cytometer (BD Biosciences, Inc.). Gates were set
with unstained cells and carbonyl cyanide-p-trifluoromethoxyphenylhydrazone
(FCCP, 50 µM) treated controls and quantified emission filters appropriate for
Alexa Fluor® 488 nm and R-phycoerythrin. Data were analyzed using
FCSExpress software (DeNovo).

Gene Expression
RNA was isolated using TRIzol reagent, and converted to cDNA using High
Capacity cDNA reverse Transcription Kit (Invitrogen). Real-time PCR was
performed using SYBR Green Fast reagent in an AB7500 machine (Applied
Biosystems). Genes of interest were normalized to the housekeeping gene
GAPDH. Forward and reverse primers were as follows: Pgc-1α, 5’TATGGAGTGACATAGAGTGTGCT-3’ and 5’-CCACTTCAATCCACCCAGAAAG3’ Primer Bank ID 6679433a1, Tfam, 5’-GAGCGTGCTAAAAGCACTGG-3’ and
5’-CCACAGGGCTGCAATTTTCC-3’ (Lagouge et al., 2006), Sirt1, 5’TGTGAAGTTACTGCAGGAGTGTAAA-3’ and 5’GCATAGATACCGTCTCTTGATCTGA-3’(Lagouge et al., 2006), Gapdh, 5’CCATCACCATCTTCCAGGAGCG-3’ and 5’-AGAGATGACCCTTTTGGC-3’
(Osuala et al., 2012). mtDNA content was measured as described previously
(Park et al., 2012).
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Oil Red O Staining
Oil Red O (5 mg/mL in isopropanol) stock stain was diluted to the working
solution (30 ml of the stock stain diluted with 20 ml of distilled water), and used to
stain for fat droplets, as previously described (Sengupta et al., 2013). Briefly, the
slides were air-dried, fixed in formalin, and briefly washed with running tap water
for 1 min. They were then rinsed with 60% isopropanol, stained with freshly
prepared Oil Red O working solution for 15-min. The staining solution was then
removed and the samples were rinsed with 60% isopropanol, rinsed further with
distilled water, and mounted using Vectashield mounting medium (Vector Labs).
Digital micrographs were obtained using a Leica DM2000 microscope, and
images were analyzed for lipid droplets using NIH ImageJ software.

Free Fatty Acid Quantification
Fatty Acids were measured using the Free Fatty Acid Quantification
Colorimetric/Fluorometric Kit (Biovision) according to the manufacturer’s
instructions. Briefly, flash-frozen embryos were homogenized for 30-sec then
centrifuged at 12,000 g for 1 min. 100 µL 1% Triton-X 100 in chloroform was
added to the supernatant. Samples were centrifuged at 12,000 g for 10 min and
lower phase was transferred and allowed to air dry, pellets were then
resuspended in fatty acid buffer. After following manufacturer’s protocol
fluorescence readings were conducted in an Envision Multilabel plate reader

57

(Perkin Elmer) (Excitation: 535nm and Emission: 590 nm) and compared to
palmitic acid standard curve. Samples were measured in duplicate.Statistics
Data are expressed as mean ± SEM. Student t-tests were performed to compare
means, with p < 0.05 required to reject the null hypothesis.

Results
ATP is depleted in adrenergic-deficient embryos
To determine if adrenergic deficiency affects embryonic metabolism, we
measured ATP and ADP concentrations in adrenergic-competent (Dbh+/- and
Dbh+/+) and deficient (Dbh-/-) embryos. Throughout this and previous studies, we
observed no significant difference in Dbh+/+ and Dbh+/- embryos for any assays
employed, and these genotypes are phenotypically indistinguishable. Thus we
have combined Dbh+/+ and Dbh+/- mice into a single group that we will hereafter
refer to as “adrenergic-competent”. Dbh-/- mice fail to produce NE or EPI, and
most will succumb to heart failure and embryonic lethality between E10.5E15.5(Thomas et al., 1995) unless rescued by maternal supplementation of
alternative catecholamine substrates(Thomas et al., 1995) or β-adrenergic
agonists, such as isoproterenol (ISO) (Thomas and Palmiter, 1998).
In the absence of any rescue, ATP concentrations begin to show
significant decreases in adrenergic-deficient embryos as early as E10.5, and
decline precipitously by E11.5 (Figure 9A). Conversely, ADP concentrations
increased over the same time period in the Dbh-/- group relative to controls
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(Figure 9B). Notably, both ATP and ADP concentrations were unchanged at
E9.5 relative to adrenergic-competent controls (Figure 9A, and 9B). Absolute
ATP, ADP, and ATP/ADP values, generated from known ATP and ADP standard
curve concentrations, are shown in Table 3 for adrenergic-competent and
deficient embryos.
This is seen most clearly by examining the ATP/ADP ratio. At E9.5, for
example, ATP/ADP ratios were virtually identical in adrenergic-competent and
deficient embryos, but then diverge dramatically over the next two days. In
control embryos, the ATP/ADP ratio steadily increases over this time period, but
in Dbh-/- embryos, this ratio drops by 50% at E10.5 and by >95% (~48-fold
reduction) at E11.5 (Figure 9C). It is important to note all embryos collected for
these analyses appeared healthy and viable, as described in the Supplemental
Methods section. In other words, the Dbh-/- embryos used throughout this study
were phenotypically indistinguishable from controls at the time of isolation.
These results demonstrate that Dbh-/- embryos exhibited an energy deficit
beginning around E10.5 that rapidly became much more severe within 24h
(E11.5).
To determine if the observed energy depletion was due to the absence of
β-adrenergic stimulation, we attempted to rescue the phenotype by providing ISO
in the maternal drinking water beginning at E8.5. When the experiment was
repeated under these conditions, the ATP deficits disappeared (Figure 9D). We
observed a 1.8-fold increase in ATP concentrations at E10.5 and a 4.5-fold
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increase in E11.5 Dbh-/- ATP concentrations after ISO treatment compared to
those observed without the addition of ISO. These results demonstrate that βadrenergic stimulation was effective at preventing the energy loss resulting from
adrenergic deficiency in developing mouse embryos.

Influence of adrenergic hormones on embryonic carbohydrate and lipid
metabolism
Carbohydrate metabolism is the principle source of energy for the
developing heart prior to birth (Cox and Gunberg, 1972; Ellington, 1987; Shepard
et al., 1970). To determine if key carbohydrate metabolites were altered in
adrenergic-deficient embryos, we measured glucose, glycogen, and lactate
concentrations in embryos isolated at E10.5 and E11.5 (Table 4). No significant
differences were observed in the concentrations of these carbohydrate
metabolites at these ages. However, lactate concentrations appeared slightly
elevated, on average, in adrenergic-deficient embryos at both E10.5 and E11.5,
but these differences were also not statistically significant. Glycogen
concentrations trended lower in the deficient group, but the results were variable
and again not found to be significantly different. The biochemical results for
glycogen were corroborated by image analysis of glycogen granules from
transmission electron microscopy (TEM) micrographs, which showed a similar
insignificant downward trend in glycogen granules at E11.5 for the adrenergicdeficient group (Table 4). We also measured free fatty acid concentrations and
lipid droplets, but found no significant differences in these either, though there
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was a downward trend in the deficient group for lipid droplets, which were
predominantly located in the liver at these stages of development. Despite these
trends, steady-state levels of free fatty acids as well as glucose, glycogen, and
lactate were relatively unchanged (no significant differences) in adrenergicdeficient embryos compared to age-matched littermate controls at E10.5 and
E11.5 (Table 4).
When we examined the rate of glycolysis, however, significant differences
were observed. To perform these measurements, we isolated and cultured
whole beating hearts from E10.5-E11.5 Dbh-/- and littermate controls, and
recorded the extracellular acidification rate (ECAR) at various intervals over a 40min period. Similar beating rates were observed in the adrenergic-competent
and deficient samples at both ages (Figure 9). At E10.5, there was little
difference in ECAR from adrenergic-deficient and control samples over the entire
40-mins (Figure 10A). At E11.5, however, adrenergic-deficient and control
ECARs were similar initially, but began to decline in the adrenergic-deficient
group after about 10-mins and continued to decline further over the next 30-mins
such that it was less than half the initial rate by 40-mins (Figure 10B). This
decline was prevented by the addition of ISO in the maternal drinking water
(Figure 10C). These results suggest that glycolysis was compromised in
adrenergic-deficient hearts by E11.5.
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Oxygen consumption rate (OCR) decrease due to absence of β-adrenergic
stimulation
Mitochondria begin to play an increasingly important role in the heart at
these early embryonic stages of development. To determine if adrenergic
hormones influence mitochondrial respiration, oxygen consumption rates (OCRs)
were measured in beating embryonic hearts isolated and cultured from E10.5
and E11.5 adrenergic-deficient and age-matched littermate control samples. At
both ages, OCR was significantly lower in the adrenergic-deficient hearts over a
35-min period as shown in Figure 12 (panels A & B). To confirm the oxygen
consumption was from mitochondrial function, we administered rotenone (0.5
µM) and antimycin A (2 µM) to adrenergic-competent isolated hearts to block
complexes I and III, which significantly decreased the overall OCR (Figure 13).
OCR increased similarly in adrenergic-deficient and competent hearts between
E10.5 and E11.5 (compare panels A & B, Figure 12), but the adrenergic-deficient
group nevertheless continued to lag significantly below the control group through
E11.5. It is important to note that hearts appeared similar and were beating
spontaneously at comparable slow but steady rates in both adrenergic-deficient
and competent hearts during the ex vivo culture period. Thus, despite the lack of
any clear differences in outward appearance or behavior, adrenergic-deficient
hearts consumed oxygen at significantly lower rates than control hearts, thereby
indicating their ability to carry out OXPHOS was significantly and substantially
decreased relative to adrenergic-competent controls. To verify this effect was
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due to the absence of adrenergic hormones, we show that rescue with ISO
restored OCRs in adrenergic-deficient hearts (Figure 12 panels C & D).

Mitochondrial biogenesis not affected by the loss of adrenergic-hormones
In theory, the lowered OCR and ATP/ADP could be due to fewer
mitochondria resulting from compromised mitochondrial biogenesis in
adrenergic-deficient hearts. To test this hypothesis, we measured expression of
key mitochondrial biogenesis genes; however, no significant alterations in mRNA
for Pgc-1α (p=0.58), Tfam (p=0.47), and Sirt1 (p=0.65) were found in E10.5
isolated hearts when normalized to the housekeeping gene Gapdh (Figure 14A).
Similar results were found at E11.5. We also measured mitochondrial DNA
(mtDNA) content present in adrenergic-deficient and control hearts, but no
significant differences were observed (Figure 14B). Although not significant,
there was a small apparent increase in mtDNA at E10.5, which may be related to
the similar upward trend seen in Pgc-1α from this group (compare Figure 14A
and 14B). These results suggest that mitochondrial biogenesis is not likely a
limiting factor in adrenergic-deficient embryos at these early stages.

Adrenergic-deficient myocytes have intact mitochondrial membranes
The decreased OCR in adrenergic-deficient hearts suggests that
mitochondrial function may be impaired. To properly function, mitochondria must
maintain membrane potentials sufficient to drive the proton gradients necessary
for OXPHOS in their inner membrane space. The fluorescent dye JC-1 can
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distinguish between mitochondria with intact membranes and those with
compromised membrane potentials via differential fluorescence emissions(Reers
et al., 1991). For example, red fluorescence (~590 nm) detects aggregates and
is indicative of healthy intact membranes, while green fluorescence (~529 nm)
detects monomers associated with perturbed mitochondrial potentials. We
employed JC-1 staining with flow cytometry in combination with laser-scanning
confocal fluorescence microscopy to assess mitochondrial membrane potential
integrity in cardiomyocytes isolated from E10.5 and E11.5 adrenergic-competent
and deficient hearts. Flow cytometry for red (aggregates) and green (monomers)
showed no difference between adrenergic-deficient and control samples at E10.5
(Figure 15A) or E11.5 (Figure 15C). Quantification of the stained primary
cardiomyocyte culture showed a red to green ratio of 3.4 ± 0.7; n=9 in the E10.5
deficient samples and 3.1 ± 0.6; n=9 in controls (Figure 15B). Similar results
were observed in the E11.5 primary cardiomyocyte cultures with the red to green
ratio of 3.4 ± 1.3; n=4 in the deficient group and 2.5 ± 0.8; n=4 in the control
group (Figure 15D). Representative mitochondrial staining with JC-1 is shown in
Figure 15E for adrenergic-competent and deficient myocytes isolated from E11.5
hearts. Despite the fact there were no significant differences in the ratio of
red/green staining in these specimens, the mitochondrial staining pattern in the
adrenergic-deficient group appeared to be less densely clustered and less wellorganized within myocytes than those typically found in age-matched adrenergiccompetent littermates, indicating there may be structural abnormalities in
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mitochondria from adrenergic-deficient embryos. At this resolution, however, it
was difficult to determine if there were truly structural anomalies in the
mitochondria, so we employed transmission electron microscopy (TEM) for these
evaluations as described below.

Mitochondrial morphology altered in adrenergic-deficient hearts
To obtain a more detailed view and assessment of mitochondrial structure
in adrenergic-deficient and control embryonic hearts, we analyzed cardiac tissue
specimens using TEM. Our results show that mitochondria within E10.5
adrenergic-deficient myocardium were enlarged and appeared swollen (Figure
16B) relative to adrenergic-competent controls (Figure 16A). Similar results were
observed in E11.5 adrenergic-deficient hearts, demonstrating elongated
mitochondria (Figure 16F) compared to adrenergic-competent samples (Figure
16E). Additionally, multiple mitochondria showed a branching and swollen
appearance (Figure 16C and 16G arrowheads). Tracings of the abnormal
shaped mitochondria observed in adrenergic-deficient hearts are shown for
E10.5 (Figure 16D) and E11.5 hearts (Figure 16H). Like E10.5 adrenergicdeficient samples, E11.5 mutants had a significantly (p<0.05) decreased number
of mitochondria per micrograph as compared to E11.5 adrenergic-competent
hearts (Table 5). While there was a decreased number of mitochondria, the
length of those present was considerably increased (p<0.0001) in the adrenergicdeficient samples versus controls (Table 5). Consequently, increased (p<0.001)
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overall mitochondrial surface area was observed within myocytes for the
adrenergic-deficient samples when compared to controls (Table 5). These
results clearly show that mitochondrial structure is significantly altered in
adrenergic-deficient embryos. On average, the mitochondria were longer, had
greater surface area, and displayed more abnormal shapes such as branch
points, curvatures, and budding bulges in their membranes compared with their
control counterparts.

Discussion
Anaerobic glycolysis is the predominant mode of metabolism of the heart
during early embryonic development, but aerobic mitochondrial metabolism
becomes an increasingly important and essential mode of energy production at
late embryonic to early fetal stages of development (Cox and Gunberg, 1972;
Ellington, 1987; Shepard et al., 1970). For example, classic studies showed that
isolated embryonic rat hearts utilized glycolytic mechanisms through E11;
however, glycolysis was not sufficient to maintain maximal heart rates at E12 or
E13 (Cox and Gunberg, 1972). Further, energy metabolism was unaffected by
the presence of oxygen at E11 in the rat, but was significantly and progressively
elevated by oxygen in E12 and E13 hearts. This embryonic-shift in metabolic
capability between E11-E12 in the rat roughly corresponds to the end of the
organogenesis period of embryonic development and the beginning of fetal
development. In the mouse, the equivalent stages of development are
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approximately E9.5-E10.5 (Theiler, 1972). It is at this embryonic/fetal juncture
when metabolic deficiencies first become apparent in Dbh-/- mouse embryos,
which lack the ability to produce the adrenergic hormones, NE and EPI.
At E9.5, there was no discernible difference in ATP or ADP concentrations
in adrenergic-deficient and control embryos, but ATP/ADP ratios began to
decline at E10.5 and much more dramatically so at E11.5 in adrenergic-deficient
embryos. It seems unlikely this decline in ATP/ADP can be fully ascribed to
glycolysis since no significant differences were observed in key glycolytic
metabolites including glucose, pyruvate, and lactate at E10.5 or E11.5. In
addition, glycolytic rates (ECAR) were virtually identical at E10.5 in adrenergicdeficient and control embryos. By E11.5, however, ECAR began to decline in the
adrenergic-deficient group, indicating that glycolytic rate was compromised. The
decline was not apparent immediately, but developed over a 15-30 min period,
and could be prevented by supplying the β-agonist, isoproterenol. At present, it
is not yet clear how β-adrenergic stimulation influences glycolytic rates in the
embryo. Potential targets include Protein Kinase A (PKA)-mediated
phosphorylation of glycolytic and glycogenolysis enzymes (Krebs and Fischer,
1956). Further study is required to determine which enzymes or other factors
may be influenced by adrenergic hormones in the embryonic condition.
As we have shown, OCR was also significantly decreased in adrenergicdeficient hearts at E10.5 and E11.5 relative to littermate controls. These results
indicate that aerobic metabolism was compromised in these embryos. In fact, it
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appeared that basal OCRs in adrenergic-deficient hearts lagged about a day
behind adrenergic-competent hearts, and were only about 50% of control levels
at E10.5 and E11.5. These effects were extinguished by supplying isoproterenol
in the maternal drinking water, thereby indicating the absence of β-adrenergic
stimulation was responsible for the declining OCRs in Dbh-/- embryos. These
results suggest that oxidative phosphorylation was impaired in adrenergicdeficient embryos.
Consistent with these observations, we found that mitochondrial structure
was significantly altered in adrenergic-deficient embryos. TEM analyses showed
that mitochondria were enlarged and more frequently displayed branching or
budding membranes in adrenergic-deficient hearts at E10.5 and E11.5. Despite
the abnormal mitochondrial morphology in these hearts, the membranes
appeared to be intact with well-formed cristae. Further, no significant alterations
in red/green fluorescence ratios were observed following application of the
mitochondrial membrane potential-sensitive dye, JC-1, in adrenergic-deficient
hearts compared with controls. These findings suggest that although the
mitochondria were larger and abnormally shaped, the observed structural
changes may represent compensatory mechanisms to try and increase ATP
production in energy-starved Dbh-/- hearts (Gomes et al., 2011; Mao et al., 2013).
Indeed, enlarged mitochondria have been associated with enhanced metabolic
output while smaller fragmented mitochondria have generally been associated
with decreased metabolic output (Knott et al., 2008; Palorini et al., 2013; Tasseva
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et al., 2013). In the present study, however, we observed enlarged mitochondria
with apparent decreased metabolic output. The phenomenon of elongated
mitochondria with diminished function has been demonstrated previously in other
models of mitochondrial dysfunction (Benard et al., 2007; Chen et al., 2003;
Mortiboys et al., 2008).
We speculated the Dbh-/- embryos may be starved for substrate
metabolites, but as indicated above, little change was observed in key
carbohydrate or lipid substrates. This result was not entirely unexpected since
glucose is known to pass freely from maternal blood supply to the embryo
(Takata et al., 1994). These results suggest that metabolic substrates did not
appear to be depleted in adrenergic-deficient embryos. It is possible, however,
the rate of substrate transport into cells and/or inner membrane space of
mitochondria could be a limiting factor in the embryos, and this will likely be an
important target for future investigations. The inability of the embryo to increase
nutrient supply and subsequently increase metabolic rate provides an
explanation for the differences observed in the embryonic versus adult Dbh-/mice, which compensate by increasing food intake and basic metabolic rates
through mechanisms that are not fully understood (Thomas and Palmiter, 1997).
The pathophysiology of adult heart failure is commonly characterized by
mitochondrial dysfunction, indicated by decreased energy production (Ingwall
and Weiss, 2004; Ventura-Clapier et al., 2004; Ventura-Clapier et al., 2011).
However, in the Dbh-/- embryos the signs of energy starvation are seen before
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any outward precursor of heart failure. Indeed, metabolic deficiencies were
observed in Dbh-/- embryos that were otherwise phenotypically indistinguishable
from adrenergic-competent controls at the time of isolation in terms of size,
morphology, color, texture, and cardiac beating activity. These results suggest
that metabolic defects likely contribute to the subsequent heart failure and
embryonic lethality in this model.
The results presented here open the door for exploration of the
mechanisms responsible for the observed energy deficits in embryos lacking the
ability to produce adrenergic hormones. Potential targets for adrenergicmediated regulation of aerobic metabolism include, but are not limited to,
electron transport chain enzymes in mitochondria such as complex I or IV, which
have both been shown to be substrates for PKA-mediated phosphorylation (AcinPerez et al., 2011; De Rasmo et al., 2011; Papa et al., 2012). Alternatively,
proteins that regulate mitochondrial structure by promoting fission or fusion (Drp1
and Mfn2) have also been shown to be subject to PKA-mediated phosphorylation
(Chang and Blackstone, 2007; Cribbs and Strack, 2007; Zhou et al., 2010), and
alterations in their activities may also be crucial for mitochondrial function in
these embryos. Yet other avenues for investigation here include ATP utilization
rates (Ingwall, 2006; Luptak et al., 2005), the creatine kinase system (De Sousa
et al., 1999; Nascimben et al., 1996), other subunits of the electron transport
chain (Chung et al., 2007; Spitkovsky et al., 2004), and regulation of the closing
of the mitochondrial transition pore, which naturally occurs at similar stages of
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development (~E10.5) in embryonic mouse hearts (Drenckhahn, 2011; Halestrap
and Pasdois, 2009; Hom et al., 2011). The G protein-coupled receptor kinase 2
(GRK2) is another attractive target since it is activated by β-adrenergic
stimulation, is essential for heart development and embryonic survival, and
appears to be an important signaling intermediary in the regulation of
mitochondrial metabolism (Chen et al., 2013; Fusco et al., 2012; Jaber et al.,
1996; Lymperopoulos et al., 2013). Future experiments are needed to
distinguish between these various possibilities.
In summary, we have shown that adrenergic hormones fulfill a critical
developmental role by serving to provide the growing embryo with sufficient
chemical energy in the form of ATP to enable successful transition from
embryonic to fetal stages. Further, our results demonstrate that adrenergic
hormones are necessary to maintain sufficient ATP/ADP, ECAR, and OCR
during late periods of embryonic development in preparation for the transition to
the fetal period. The discovery of these influential regulatory connections
between adrenergic hormones and embryonic energy metabolism opens new
paths for the study of cardiovascular development that could give rise to novel
therapeutic targets and strategies for treating congenital heart defects (Chin et
al., 2012; Krebs et al., 2011) as well as adult forms of heart disease.
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Tables

Table 3 ATP, ADP, and ATP/ADP ratio values of adrenergic-deficient and
control embryos.

E11.5

E10.5

E9.5

[ATP]
(nmol/mg
protein)

[ADP]
(nmol/mg
protein)

ATP/ADP
Ratio
(AU)

Competent

40.6 ± 10.7

19.8 ± 6.6

3.9 ± 1.2

Deficient

32.4 ± 8.3

10.8 ± 2.9

3.8 ± 1.2

Competent

26.8 ± 3.1

9.1 ± 1.9

5.1 ± 1.0

Deficient

19.5 ± 7.3

9.9 ± 4.1

2.6 ± 0.8

Competent

7.6 ± 0.5

0.8 ± 0.06

9.4 ± 1.3

Deficient

1.0 ± 0.4***

4.3 ± 1.3**

0.2 ± 0.03***

Number
of
samples
12
6
13
5
8

4

Values obtained from standard curve of known ATP and ADP concentrations.
Data are represented as mean±SEM. *, p<0.05; **, p<0.01; ***, p<0.001
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Table 4 Carbohydrate and Lipid Metabolite Concentrations.

E10.5

E11.5
Competent

Deficient

pvalue

436±27
n=8

421±44
n=7

0.77

0.45

9.9±6.5
n=4

4.3±2.2
n=3

0.51

6.2±0.9
n=46

0.30

4.8±1.0
n=18

3.3±0.7
n=23

0.20

250±50
n=6

422±107
n=6

0.17

293±37
n=6

416±78
n=6

0.18

Lipid (liver)
Droplets
(per sq. mm)

5015±677
n=10

3528±416
n=14

0.06

5866±598
n=16

3988±869
n=16

0.09

Free Fatty Acids
(nmol/mg
protein)

1.6±0.2
n=10

1.5±0.2
n=10

0.86

1.5±0.1
n=8

1.5±0.3
n=7

0.92

Competent

Deficient

Glucose
(nmol/mg
protein)

313±17
n=10

260±26
n=9

Glycogen
(nmol/mg
protein)

5.8±1.4
n=4

7.5±1.5
n=4

Glycogen
Granules
(% per nm2)

5.0±0.6
n=32

Lactate
(nmol/mg
protein)

pvalue

0.09

Values obtained from standard curve of known concentrations. Data are
represented as mean±SEM.
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Table 5 Quantification of transmission electron microscopy.

Number per 17.5
µm2

E10.5
AdrenergicCompetent

E10.5
AdrenergicDeficient

E11.5
AdrenergicCompetent

E11.5
AdrenergicDeficient

12.3 ± 0.5
n=59

10.4 ± 0.4**
n=103

13.9 ± 1.1
n=38

11.0 ± 0.7*
n=38

715.9 ± 13.7
n=701

775.9 ± 14.6**
n=1074

637.5 ± 17.4
n=529

888.5 ± 27.9***
n=418

245 ± 10.4
n=171

324.9 ± 21.1***
n=140

204.8 ± 10.6
n=166

362.8 ± 28.7***
n=127

Length (nm)

Surface Area
(µm2)

Data are expressed mean ± sem. *, p<0.05; **, p<0.01; ***, p<0.001
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Figures

1.5

A

C

***

1.5

0.5

*
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1.0

0.5

+
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D
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1.5
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(Fold-Change)

*
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(Fold-Change)

ISO

Adrenergic-Competent
Adrenergic-Deficient

1.5

ATP/ADP Ratio
(Fold-Change)

1.0
ATP
(Fold-Change)

[ATP]
(Fold-Change)

*

6
4
2

*

1.0

0.5

13

10

4

10

-

+

-

+

0.0

0
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E9.5

E10.5

E11.5

E10.5
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Figure 9 ATP, ADP and ATP/ADP measurements in adrenergic-deficient
embryos compared to controls.
(A) ATP, (B) ADP, and (C) ATP/ADP ratio measurements at E9.5, E10.5, and
E11.5 in adrenergic-competent (black bars) and adrenergic-deficient littermates
(white bars). (D) ATP measurements at E10.5 (n≥10) and E11.5 (n≥4) in
adrenergic-deficient embryos with and without isoproterenol. Fold-change
calculations were generated from steady-state ATP and ADP concentrations. *,
p<0.05; **p<0.005; ***, p<0.001.
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Figure 10 Beating rates of embryonic mouse hearts after 24-hrs of ex vivo
culture.
Data are presented as mean ± SEM.
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Figure 13 OCR is due to mitochondrial function in isolated embryonic
hearts.
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Figure 15 Analysis of mitochondrial membrane potentials in adrenergicdeficient and control myocytes using flow cytometry and fluorescence
microscopy with JC-1 dye.
(A and C) Representative scatter plots of flow cytometry with red and green
fluorescence from JC-1 dye in adrenergic-deficient and adrenergic-competent
E10.5 and E11.5 embryonic primary cardiomyocytes. Adrenergic-competent
samples (red) and adrenergic-deficient samples (blue) in histogram overlay. (B
and D) Ratio of red/green fluorescence in E10.5 and E11.5 adrenergiccompetent (white bars) and deficient (black bars) samples. Numerical values in
the columns refer to the number (n) of samples analyzed. (E) Representative
scanning laser confocal microscopy of JC-1 dye in E11.5 primary
cardiomyocytes. Scale bar, 10 μm.
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Figure 16 Ultrastructural analysis of mitochondria in adrenergic-deficient
and control hearts following evaluation of TEM images.
Mitochondrial morphology in adrenergic-competent and deficient E10.5 (compare
A and B) and E11.5 (compare E and F) myocytes. (C and G) Branched
(arrowheads) and swollen mitochondria in adrenergic-deficient samples. (D and
H) Representative tracings of abnormally shaped mitochondria in adrenergicdeficient samples. (I) Number of mitochondria per defined micrograph area (17.5
µm2) in E10.5 and E11.5 adrenergic-competent (black bars) and deficient (white
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bars) samples. (J) Mitochondrial length in E10.5 and E11.5 adrenergiccompetent (black bars) and deficient (white bars) samples. (K) Surface area of
mitochondria in E10.5 and E11.5 adrenergic-competent (black bars) and deficient
(white bars) samples. Abbreviations: m=mitochondria; n=nucleus. *, p<0.05; **,
p<0.01; ***, p<0.001. Scale bar= 500 nm.
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CHAPTER FOUR:
ECHOCARDIOGRAPHIC ANALYSIS OF LEFT VENTRICULAR
FUNCTION IN STRESS-CHALLENGED AGED MICE: EFFECTS OF
GENDER (SEX) AND MENOPAUSE
Abstract
To investigate age, sex, and menopausal differences left ventricular (LV)
function was evaluated using high-resolution ultrasound in age-matched male,
pre- and post-menopausal female mice hearts at from nine months to 21 months
old at baseline and in response to epinephrine and immobilization stress. We
found a more robust response to epinephrine stimulation in males at nine months
compared to females. After the induction of menopause, similarities were found
between males and menopausal females with regards to end systolic and
diastolic volumes, fractional shortening and cardiac output. This trend persisted
when the same group of mice underwent immobilization stress. These data
demonstrate that biological sex and menopause have significant influence on LV
function in response to various stressors in mice. Lastly, we found the
distribution of adrenergic cell population was void in the aged cycling female
heart and only after the induction of menopause are adrenergic cells observed in
the left heart. This indicates differential adrenergic cell populations are present in
male versus females and pre- versus post-menopausal females.
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Introduction
Heart failure (HF) afflicts populations across the globe with an annual
mortality rate of nearly 10% of the population. Male HF patients often exhibit a
reduced ejection fraction (EF) compared to a preserved EF in female patients
(Hogg et al., 2004; Regitz-Zagrosek et al., 2010). Reduction in EF is correlated
with an overall drop in heart function and, ultimately, survival. This interesting
gender difference has been highly studied in the clinical settings (Cleland et al.,
2003; Regitz-Zagrosek et al., 2007) and in animal models (Du, 2004); however,
mechanistic regulation of these observed gender differences in relation to the
progression and prognosis of heart failure remains obscure. These studies
demonstrate a need for divergent treatment of male versus female heart failure
patients.
Additionally, stress-induced cardiomyopathies, such as Takotsubo
cardiomyopathy, predominantly afflict post-menopausal women (greater than
82% of such cases) who have experienced a sudden emotional shock (H. Sato,
1990). These women display left ventricular (LV) dysfunction characterized by
hypo- or a-kinetic regions, particularly near the apex and often have elevated
plasma catecholamines, and are at high risk of arrhythmia and sudden cardiac
death if left untreated (Kume et al., 2008; Wittstein et al., 2005; Yoshida et al.,
2007). At present, it is not entirely clear why only specific regions of the LV are
primarily affected, nor is it understood why postmenopausal women are
particularly susceptible to these types of stress cardiomyopathies (Baker, 2014).
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The effects of age, sex and menopausal status on cardiovascular function
have been investigated individually; however these three important factors
contributing to left ventricular function have not been looked at together, nor in
response to stress stimuli. Additionally, very few studies have been conducted in
vivo. Myocardial response to adrenergic hormones has been extensively
investigated in vitro and the effects of sex and menopause have been
incorporated into these types of studies (Luczak and Leinwand, 2009; McIntosh
et al., 2011; Schwertz et al., 1999; Vizgirda et al., 2002).
Recent work has shown distribution of historical and/or active intrinsic
adrenergic derived myocardium in young adult mice follows a similar pattern to
that seen in regions of the left heart most commonly affected in stress induced
cardiomyopathy patients (Osuala et al., 2011). These areas include the base,
mid and apical sections of the left heart. In addition, Kume et al. showed
increased catecholamines concentrations in the apex as compared to the base in
five confirmed cases of Takotsubo cardiomyopathy (Kume et al., 2008). These
results suggest differential local catecholamine concentrations in apical versus
basal regions of the left heart, likely originating from the intrinsic adrenergic cells
located in these regions (Baker, 2014).
We hypothesized there are inherent differences between in vivo left
ventricular function due to sex, age, and menopausal status and tested this
hypothesis by injecting epinephrine before and after menopause induction in
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mice while performing high-resolution echocardiography. Further, to recapitulate
an emotional stress paradigm, immobilization stress was conducted and cardiac
function was monitored using echocardiography. Upon conclusion of all
functional studies, the hearts were then excised and viewed for histological
distribution of adrenergic myocardium.
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Materials and Methods
Mice
All procedures and handling of mice were conducted in accordance with The
University of Central Florida Institutional Animal Care and Use Committees.
PnmtCre/Cre and ROSA26βgal/βgal mice were bred and maintained as previously
described. PnmtCre/Cre and ROSA26βgal/βgal were mated and resulting offspring
(Figure 17) were aged to 9 months before the first ultrasounds were performed.

Epinephrine Injections and Echocardiography
Mice were anesthetized with 2% isoflurane for duration of epinephrine injection
studies. Body temperature was maintained between 36-37ºC using a heated
platform and monitored with rectal probe. Transthoracic echocardiography was
performed using a Vevo® 2100 (Visual Sonics, Toronto, Canada) system
equipped with a high frequency 40 MHz transducer. Recordings were conducted
every 5 min for 20 min to avoid any artifact from isoflurane. Intraperitoneal
epinephrine injections were administered at a dose of 50 mg/kg body weight.
Recordings continued for 40 min at 5 min intervals. Calculations were made
from recordings taken directly prior to injection and at peak heart rate after
injection.
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Immobilization and Echocardiography
Mice were anesthetized with 2% isoflurane for hair removal and baseline
recordings. Body temperature was maintained using an external heating pad.
Mice were restrained in the supine position with limbs secured in place with
perforated tape. After baseline recordings anesthesia was removed and mice
were allowed to become fully conscious. Transthoracic echocardiography was
performed using a Vevo® 2100 (Visual Sonics, Toronto, Canada) system
equipped with a high frequency 40 MHz transducer. Recordings were taken at
15 min, 1 hr, and 2 hr timepoints. Calculations were made from recordings taken
at baseline and 2 hr.

Menopause Induction
Menopause was chemically induced using 4-vinylcyclohexane diepoxide (VCD)
(160 mg/kg/day) intraperitoneal injections for 15 consecutive days as previously
described (Hoyer and Sipes, 2007). Vehicle control (peanut oil) injections were
performed in parallel.

Vaginal Cytology
Menopause was confirmed by persistent diestrus for 5 consecutive days using
vaginal cytology in both VCD and vehicle control groups. Briefly, sterile normal
saline (20 µL) was flushed in vaginal cavity and collected on microscope slide
daily. Slides were examined using 10X objective light microscopy using a Leica
DM2000 microscope with a Leica DFC295 camera for distribution patterns of cell
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type present. Upon examination of estrous cycle of control injection females,
forty percent of the mice were determined to have undergone a natural
menopause. Five days of persistent diestrus was classified as menopausal, if a
mouse cycled from proestrous to estrus to metestrus to diestrus then back to
proestrus, this indicated a typical 4 day estrus cycle and that mouse was
classified as cycling. Diestrus is characterized by primarily the presence of
leukocytes, proestrus by nucleated epithelial cells, estrus by cornified anucleated
cells, and metestrus by a combination of all three cell types.

Corticosterone Measurements
Plasma corticosterone levels were measured following manufacturer’s protocol
using an ELISA (rat/mouse) kit from IBL-America (Minneapolis, MN).

Histological Preparations
Pnmt+/Cre ROSA26+/βgal mice aged 9 months and 21 months were sacrificed by
cervical dislocation or swift decapitation. The heart was rapidly removed and
retrogradely perfused through the aorta with phosphate-buffered saline then 2%
paraformaldehyde. Adrenal glands were removed and processed similarly as
hearts. Tissue was then placed in 2% paraformaldehyde for 24 hr at 4ºC then
moved to 30 % sucrose with 0.02% sodium azide for storage. For sectioning the
hearts and adrenal glands were embedded in Tissue-Tek® OCT compound (EM
Sciences, Hatfield, PA) and sectioned at 12 micron using a Leica (CM1850
cryostat) at -20-24ºC, sections were stored at -20 ºC for subsequent staining.
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Tissue sections were stained for β-galactosidase activity as previously described.
Images were taken using a Leica L2 microscope and Leica EC3 camera and
quantification of blue pixels were determined using Adobe Photoshop magic
wand tool.

Statistics
Data are expressed as mean ± S.E.M. Student t-tests were performed to
compare means between two groups and ANOVA performed between three
groups, with p < 0.05 required to reject the null hypothesis.
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Results
Pre-menopausal EPI Challenge
At 9 months of age male and female mice were subjected to baseline
echocardiography to assess LV function. After 20 mins epinephrine (EPI, 50
mg/kg) was injected into the intraperitoneal cavity. Baseline heart rate was
significantly higher in the female mice group as compared to the males, however,
the males responded more robustly to the EPI than females (Figure 18A).
Baseline left ventricular end diastolic and systolic volumes were significantly
greater in the males as compared to females at baseline (Figure 18B and C),
most likely due to the larger size of males compared to age matched females.
Notably, a higher percent change in end diastolic and systolic volumes was seen
in males as compared to females after EPI injections (Figure 18F). Stroke
volume was also increased in males as compared to females at baseline and
after EPI injections (Figure 18D). A significant increase in stroke volume after
EPI injection was also observed in males as compared to females (Figure 18F).
Lastly, cardiac output was significantly higher in males than females before and
after EPI injections, with both groups displaying a similar increase after the
injection (Figure 18E and F). Complete echocardiographic measurements at
baseline and response to EPI are shown in Table 6. These results show that
males have a more robust response to EPI as compared to age matched
females.
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Post-menopausal EPI Challenge
After induction and confirmation of menopause, EPI injections were
repeated in males and females, only the female group was divided into premenopausal (i.e. cycling) and post-menopausal (i.e. non-cycling) subgroups. At
baseline there were no differences in heart rate between the three groups (Figure
19A). After the injection of EPI significant differences were observed between
the pre-menopausal females, post-menopausal females and male heart rates
(Figure 19A), though the percent increases after EPI injections were not different
between the three groups (Figure 19F). In addition, end systolic and diastolic
volumes were significantly different between the three groups at baseline, though
end diastolic volumes varied between the groups after EPI injections (Figure 19B
and C). Stroke volumes were similar between the groups at baseline and only
after EPI injections were differences observed between males, cycling and
menopausal females (Figure 19D). A similar pattern was observed with cardiac
output, demonstrating differential effects to EPI measured between the three
groups, but not at baseline (Figure 19E). Complete echocardiographic
measurements at baseline and response to EPI are shown in Table 7.

Age Effects
Next, we investigated the effects of age from 9 months to 21 months in
males and females when stress was induced with EPI injections. Heart rate was
not significantly different when comparing males and females at nine months
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versus eighteen months of age before and after EPI injections (Figure 20A and
21A). End systolic (p<0.001) and diastolic (p<0.05) volumes increased
significantly only in males between nine and eighteen months, after EPI these
differences were no longer measured (Figure 20B and C). Stroke volume was
significantly higher in males after aging (Figure 20D). However, it was drastically
decreased in females at eighteen months compared to stroke volume at nine
months (Figure 21D). Cardiac output was highly similar between the ages in
both genders (Figure 20E and 21E).

Sex and Menopausal Status in Response to Immobilization Stress
Immobilization stress was utilized to recapitulate the emotional stress that
is typically a precipitating factor in stress-induced cardiomyopathies. Baseline
heart rates were not different between males, cycling and menopausal females
(Figure 22A). However, after 2 hours of immobilization stress (IMO) ANOVA
statistics determined a significant (p<0.05) variation between the three groups.
End systolic volume showed no statistically significant differences (Figure 22B)
and end diastolic volume demonstrated variability only after IMO stress (Figure
22C). Stroke volume showed no difference at baseline however, after IMO
cycling females had significantly lowered values as compared to males and
menopausal females, which were not different from one another (Figure 22D).
Similarly, cardiac output was significantly different amongst the three groups at
baseline with cycling females have the lowest values (Figure 22E). All three
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groups had similarly high blood corticosterone levels as compared to unstressed
control mice (Figure 23), thereby confirming the mice were clearly stressed
physiologically. Complete echocardiographic measurements at baseline and
response to EPI are shown in Table 8.

Histological Assessment of Adrenergic Cell Distribution
To determine the localization of adrenergic-derived myocardium, we
utilized X-gal staining to identify positive cell populations. At 8-9 months hearts
and adrenals were excised from male and female mice and frozen sections were
stained. Interestingly, the male heart sections showed a robust staining pattern
in the left heart and especially in the basal regions (Figure 24B). However, little
to no positive staining was observed in the female left heart; however staining
was readily present in the female 9 month adrenal gland (Figure 24A). At 21
months all mice were euthanized and hearts and adrenals removed and
processed as indicated in Materials and Methods section. By this age no
staining was observed in the male hearts or cycling female hearts, however, blue
X-gal+ cells were clearly present in the postmenopausal hearts (Figure 24C-E).
Staining was observed in the adrenal gland of all 21 month mice (Figure 25).
Quantification of the X-gal+ pixels shows a significant increase in staining the
males at 9 months compared to aged matched females (Figure 24F).
Surprisingly, these X-gal+ pixels were significantly decreased in the males at 21
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months, still not present in premenopausal females and drastically increased in
postmenopausal females by 21 months (Figure 24F).
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Discussion
The stress-induced cardiomyopathy, Takotsubo syndrome, is
characterized by predominately affecting postmenopausal women, increased
circulating catecholamines, and hypo or a-kinesis of the mid and apical left
ventricle (Cocco and Chu, 2007; Wittstein et al., 2005). To recapitulate this
syndrome we increased catecholamine levels by injecting EPI (i.p.) and inducing
emotional stress by immobilization and observed cardiac function via highresolution echocardiography (Shao et al., 2013; Ueyama, 2004). Additionally, as
age and menopause are common features of this syndrome, mice were aged
past nine months and menopause was induced and cardiac function studies
were repeated. Lastly, using a β-galactosidase reporter we observed the
localization of intrinsic adrenergic cells
While little to no apical ballooning was observed after injection of EPI or
immobilization stress was observed via high-resolution echocardiography,
interesting results were found regarding differences between age, sex, and
menopausal status in response to stress paradigms. We compared the effects of
left ventricular function using high-resolution ultrasound before and after stress
response.
In parallel with other reported cases of stress response in males versus
females, male nine month mice had a more robust response to EPI stimulation
as compared to females (Schouwenberg et al., 2006). Others have reported a
larger response in males to adrenergic stimulation, in vivo, isolated heart
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preparations, as well as skinned myocytes (Gao et al., 2003; Schwertz et al.,
1999; Scott et al., 2007). Investigation into the mechanism behind the greater
sensitivity in males revealed a two-fold greater beta-adrenergic receptor density
in male left ventricular membranes (Vizgirda et al., 2002). However, the function
of these receptors has been questioned by many (Hinojosa-Laborde et al., 1999)
and never been examined in vivo experimentation.
Premenopausal female patients (less than 65) are known to have better
outcomes to hypertension, aortic stenosis and hypertrophic cardiomyopathy and
preserved left ventricular ejection fraction in heart failure (Regitz-Zagrosek et al.,
2010). However, these statistics change drastically after the age of 65 and
initiation of menopause (Luczak and Leinwand, 2009). Consequently, the role of
estrogen and cardiovascular function has been extensively studied, though few
studies have investigations have been conducted in vivo (Dubey and Jackson,
2001; McIntosh et al., 2011; Schaible et al., 1984). Here we show differences
between males, cycling and menopausal females when measuring heart rate
response, stroke volume and cardiac output to EPI stimulation.
Additionally, our results demonstrate a similar aging pattern observed
previously, that males have a significant increase in left ventricular end systolic
and diastolic volume with age (Grandi et al., 1992). Whereas females show left
ventricular stiffness exhibited by a drastic decrease in stroke volume over nine
months of age (Borlaug et al., 2013).
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Our studies also investigated the effects of an emotional stress paradigm,
immobilization stress, with regards to gender and menopausal status. Here we
show menopausal females have similar response to stress as males with regards
to heart rate response, stroke volume and cardiac output. Cycling females have
a decreased stroke volume as well as cardiac output compared to age matched
male and menopausal female mice.
To understand the distribution of adrenergic derived myocardium with
regards to age, gender, and menopausal status hearts were excised, sectioned,
and stained for X-gal+ cells. The young adult mouse (3-8 weeks) was shown to
have a distinct left sided distribution of intrinsic cardiac adrenergic cells. This
characteristic pattern was observed in males at nine months of age, however,
little to no ICA cells were observed in the myocardium of the cycling female heart
at nine months. At 21 months ICA cells were no longer observed in the male
heart, interestingly though the ICA cells were not observed in the menopausal
female heart. One studied examined the rate of myocyte turnover in the aging
heart, revealing the human male heart loses approximately 1 gram of myocytes
per year, this is not seen in female hearts (Olivetti et al., 1995).
Controversial research has been conducted on whether estrogen levels
regulate adrenergic receptors receptor and expression, especially in the heart.
One study showed an upregulation of the β-1 adrenergic receptor in menopausal
rats (Thawornkaiwong et al., 2003). While others have shown increased betaadrenergic responses in male left ventricles, thought to be due to increased
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calcium influx (McIntosh et al., 2011). Unfortunately, there has been no research
conducted in adrenergic receptor sensitivity to estrogen in whole hearts.
Here we have shown a differential left ventricular response to stressors in
males and females. Interestingly, trends toward similar LV responses to stress
(EPI and IMO) were seen between males and menopausal females as compared
to age-matched cycling females. Additionally, a drastic reappearance of intrinsic
cardiac adrenergic cells were observed and quantified in the menopausal left
ventricular and apical regions of the heart. This sudden reappearance may
account for a higher incidence of takotsubo cardiomyopathies observed in postmenopausal females due to higher local catecholamine release. However, future
studies are necessary to determine if this is the pathogenesis of stress-induced
cardiomyopathies.
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Tables

Table 6 Echocardiography results for 9 month male and female mice at
baseline and after EPI (50 mg/kg, i.p.)

Baseline
Males
n=28

Females
n=30

Heart Rate (bpm)

451.8±7.5

484.5±9.0

End Systolic LV
Volume (µL)

17.0±0.9

End Diastolic LV
Volume (µL)

Epinephrine

p-value

Males
n=28

Females
n=30

0.007***

526.5±5.0

536.0±5.8

0.2

12.7±0.7

0.0006***

12.0±1.0

11.6±0.8

0.8

56.7±1.9

43.3±1.5

<0.0001***

48.4±2.3

41.5±1.3

0.01*

Stroke Volume
(µL)

39.7±1.7

30.6±1.2

<0.0001***

36.4±1.9

29.9±1.1

0.004**

Ejection Fraction
(%)

69.6±1.4

70.5±1.4

0.7

75.0±1.9

72.2±1.7

0.3

Fractional
Shortening (%)

19.1±1.3

20.1±1.0

0.5

21.1±1.3

19.3±1.2

0.3

Cardiac Output
(mL/min)

18.1±0.9

14.7±0.6

0.002**

19.2±1.0

16.1±0.6

0.01**

Data are represented as mean±SEM. *, p<0.05; **, p<0.01; ***, p<0.001
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Table 7 Echocardiography results for 18 month male, cycling and
menopausal female mice at baseline and after EPI (50 mg/kg, i.p.)

Baseline
Males
n=6

Cycling
Females
n=6

436.8±13.9

460.3±18.5

443.1±9.2

0.5

510.6±10.2

557.7±9.3

537.1±8.1

0.02*

End Systolic LV
Volume (µL)

27.3±2.6

13.5±2.6

23.1±2.4

0.01*

11.2±2.2

7.1±0.8

13.6±2.5

0.2

End Diastolic LV
Volume (µL)

66.3±4.8

46.2±1.5

58.6±2.8

0.004**

57.0±3.1

37.9±3.0

49.1±3.5

0.01*

Stroke Volume
(µL)

39.0±3.2

32.7±1.3

35.5±1.7

0.2

45.8±3.0

30.8±2.5

35.6±2.1

0.004**

Ejection Fraction
(%)

59.5±2.9

71.8±4.6

61.5±2.6

0.06

81.1±3.2

82.2±1.6

74.1±3.0

0.1

Fractional
Shortening (%)

14.6±2.9

27.0±3.6

20.7±2.4

0.05*

24.6±3.1

29.2±1.7

25.4±2.5

0.5

Cardiac Output
(mL/min)

16.9±1.0

15.1±0.9

15.7±0.8

0.5

23.3±1.4

17.2±1.5

19.0±1.0

0.02*

Heart Rate (bpm)

Menopausal
Females
n=12

Epinephrine
p-value

Males
n=6

Cycling
Females
n=6

Menopausal
Females
n=12

Data are represented as mean±SEM. *, p<0.05; **, p<0.01; ***, p<0.001

111

p-value

Table 8 Echocardiography results for 21 month male, cycling and
menopausal female mice at baseline and immobilization stress

Baseline
Males
n=6

Cycling
Females
n=6

Menopausal
Females
n=11

Immobilization
p-value

Males
n=6

Cycling
Females
n=6

Menopausal
Females
n=11

p-value

465.5±33.0

398.4±8.9

416.8±11.0

0.07

657.7±15.3

692.5±7.5

687.0±5.8

0.05*

End Systolic LV
Volume (µL)

44.4±7.6

34.6±6.5

36.1±4.7

0.5

5.1±2.9

1.1±0.4

2.1±0.4

0.2

End Diastolic LV
Volume (µL)

85.5±10.1

64.2±9.7

71.8±5.5

0.2

37.9±4.0

24.0±2.8

33.6±2.5

0.03*

Stroke Volume
(µL)

41.1±4.1

29.6±4.3

35.7±3.3

0.2

32.7±2.3

22.9±2.6

31.5±2.3

0.04*

Ejection Fraction
(%)

51.0±6.6

47.8±4.1

51.9±5.1

0.9

88.6±5.2

95.6±1.2

94.1±0.9

0.2

Fractional
Shortening (%)

26.8±4.7

24.0±2.5

27.2±3.3

0.8

61.6±5.9

71.8±3.2

68.6±2.2

0.2

Cardiac Output
(mL/min)

18.8±1.6

11.6±1.6

14.9±1.4

0.03*

21.5±1.6

15.9±1.8

21.7±1.6

0.06

201.3±17.1

194.0±19.9

175.1±10.7

0.4

198.4±27.4

155.4±21.9

158.7±9.0

0.2

Heart Rate (bpm)

LV Mass (mg)

Data are represented as mean±SEM. *, p<0.05; **, p<0.01; ***, p<0.001
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Figures

B

A
ROSA26βgal/βgal

PnmtCre/Cre

ROSA26+/βgal Pnmt+/Cre

Figure 17 Schematic of mouse model.
(A) PnmtCre/Cre and ROSA26βgal/βgal homozygous mice mating scheme and
resulting heterozygous offspring genotypes. (B) Recombination of Rosa26
reporter mice and Pnmt-Cre mice results in robust expression of LacZ gene.
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Figure 18 EPI injection of males and pre-menopausal 9 month old mice.
(A) Heart Rate (B) End Systolic Volume (C) End Diastolic Volume (D) Stroke
Volume (E) Cardiac Output B-mode ultrasound analysis of 9 month old male and
female mice before and after EPI challenge. (F) Percent change calculated in
response to EPI in male and female mice. n=28 males and 30 females. Data
represented as mean ± SEM. *, p>0.05; **, p>0.01; ***p>0.001.
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Figure 19 EPI injection of males, pre and post-menopausal females at 18
months.
(A) Heart Rate (B) End Systolic Volume (C) End Diastolic Volume (D) Stroke
Volume (E) Cardiac Output B-mode ultrasound analysis of 18 month old male
and female (cycling and menopausal) mice before and after EPI challenge. (F)
Percent change calculated in response to EPI in male and female (cycling and
menopausal) mice. n=6 males, 6 cycling females and 12 menopausal females.
Data represented as mean ± SEM. *, p>0.05; **, p>0.01.
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Figure 20 Effects of age and EPI in males.
(A) Heart Rate (B) End Systolic Volume (C) End Diastolic Volume (D) Stroke
Volume (E) Cardiac Output B-mode ultrasound analysis of 9 and 18 month old
male mice before and after EPI challenge. (F) Percent change calculated from 9
months to 18 months in response to EPI. n=28 at 9 months and 6 at 18 months.
Data represented as mean ± SEM. *, p>0.05; **, p>0.01; ***p>0.001
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Data represented as mean ± SEM. *, p>0.05.
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CHAPTER FIVE: CONCLUSIONS
Cardiovascular disease is the primary cause of death in adults in the
United States and accounts for 26.6 percent of all infants that die of congenital
birth defects. Adrenergic hormones are known regulators of cardiovascular
function in both embryos and adults, they are mediators of stress responses and
have profound stimulatory effects on cardiovascular function. My thesis
addressed critical questions regarding the involvement of catecholamines in the
embryonic heart and the role of catecholamines in cardiac function in young and
aged male and female hearts. I explored the roles of adrenergic hormones in the
development of the embryonic conduction system as well as showed a link
between adrenergic-hormones and mitochondrial functional maturation during
embryogenesis. Further, I performed longitudinal high-resolution
echocardiography on male and female mice incorporating menopausal status as
a variable and tested the effect of stress on heart function by the injection of
epinephrine and immobilization.
The major conclusions found from the second chapter of work presented
here include:
1. Adrenergic deficiency leads to decreased connexin 43 in embryonic
(E)10.5 atrioventricular junctional regions but not E9.5 mouse
hearts
2. Atrioventricular conduction is significantly slower in adrenergicdeficient hearts
3. Arrhythmic activity is significantly induced in adrenergic-deficient
hearts compared with adrenergic-competent controls
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These findings indicate that adrenergic hormones are critical for the
development of the cardiac conduction system. Disruption of this key signaling
pathway either by genetic anomalies or pharmacological intervention could result
in permanent cardiovascular conduction defects. To further understand the
nature of the atrioventricular delay observed in the adrenergic-deficient hearts
and the association, if any, of decreased Cx43 the use of CRISPR (clustered
regularly interspaced short palindromic repeats)/Cas9 modeling could provide a
powerful genetic tool (Mali et al., 2013). The Dbh gene could easily be disrupted
in a Cx43 overexpression mouse model (Ewart et al., 1997) using these new
technologies and creating a novel transgenic colony. Again, utilizing the
microelectrode arrays we would determine if the loss of adrenergic hormones
slow the propagation of the conduction system from the atrium to the ventricle
through the A-V region in this unique model. Further, the characterization of
Cx43 protein levels at E9.5-E11.5 in the adrenergic-deficient embryonic hearts
will prove incredibly informative. While, we do see a decrease in
immunofluorescence staining of Cx43, a direct measure of protein content would
elucidate if there is true down regulation of this important gap junction protein in
an adrenergic-deficient state. Lastly, as mentioned previously the gene and
protein levels of connexin 45, 40, and 37.5 would provide information if there is
any compensation by other gap junction proteins that are known to be expressed
in the early heart.
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The major conclusions found from the third chapter of work presented
here include:
1. Adrenergic hormones are necessary to maintain sufficient
ATP/ADP ratios
2. Extracellular acidification rates and oxygen consumption rates are
significantly decreased in adrenergic-deficient hearts during late
periods of embryonic development
3. Metabolic steady-state substrate levels are unaffected due to the
loss of adrenergic hormones
4. Mitochondrial biogenesis genes are unaffected due to the loss of
adrenergic hormones
5. Mitochondrial membrane potential is similar between adrenergicdeficient and competent embryonic hearts
6. Adrenergic hormones influence embryonic cardiac mitochondrial
morphology
The loss of adrenergic hormones results in a severe energy deficiency in
the developing embryonic heart during the critical transition from embryonic to
fetal development. This period coincides with the “embryonic shift” from mainly
glycolytic mechanisms to oxidative phosphorylation energy production. Thus
adrenergic hormones could be a major driving factor for this shift in energy
production modalities.
Potential exploration into the involvement of catecholamines and the
mechanism(s) that drive this shift will provide knowledge of the basic
organization of the energy metabolism system within mammalian development.
Possible explanations for the necessity of adrenergic hormones in up regulation
mitochondrial activity could involve the assembly of the supercomplexes
composed of the electron transport complex. While the machinery of each
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complex (I-V) is maternally inherited, and present from fertilization, the
organization of these individual complexes is a multifaceted and understudied
field. It could conceivably be the presence and PKA stimulation driven by
adrenergic hormones that facilitates the joining of the complexes into a functional
supercomplex.
Additionally, a prominent feature of the work discussed in this chapter
includes irregularly shaped and elongated mitochondria. The mechanistic
rationale behind this intriguing finding is currently unknown, however, future
studies involve the examination of mitochondrial fission and fusion genes. The
fission genes include dynamin-related protein 1 (Drp1) and fission 1 (Fis1) and
the mitochondrial fusion genes localized to the outer membrane are mitofusin 1
(Mfn1) and mitofusion 2 (Mfn2). Additionally, the inner membrane fusion gene is
optic atrophy 1 (Opa1) (Knott et al., 2008). While the gene expression levels of
these fission/fusion regulators may be informative in determining a causal nature
of the mitochondrial morphological abnormalities observed in the adrenergicdeficient embryonic heart, protein levels, as well of phosphorylation status could
be of greater enlightenment. Drp1 for example is known to be regulated by PKA
phosphorylation on residue S656 in rats. This phosphorylation negatively
regulates Drp1 and thus inhibits fission (Chang and Blackstone, 2007). Similarly,
Mfn2 was discovered to contain a PKA phosphorylation site, S442 in rats. While
the rate of fusion was not examined in the phospho-deficient of phospho-mimetic
states the effects of vascular smooth muscle cell proliferation as a result of Mfn2
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was found to be highly correlated with the phosphorylation status (Zhou et al.,
2010).
An interesting feature of the Dbh-/- embryos is the subviability seen in the
maternal heterozygous as compared to the complete embryonic lethality
observed in the maternal homozygous state. It has been hypothesized the
explanation for this phenomenon is due to maternal adrenergic hormonal
influence (Thomas et al., 1995). However, mitochondria and the mitochondrial
genome, containing any mutations, are inherited solely from the maternal egg.
Within all mitochondrial dysfunction models a threshold effect occurs wherein the
mutational load reaches a point the phenotype presents itself and under this level
the phenotype is muted. A potential future direction would be to perform a
microinjection of eggs that have undergone in vitro fertilization from heterozygous
(Dbh+/-) dam and sire into a homozygous (Dbh-/-) pseudopregnant female. Within
this investigation one could test if the lack of maternal hormones cause the early
embryonic lethality or if the incomplete penetrance of the mitochondrial
mutational load inherited from a heterozygous mother is the explanation for the
subviability
The major conclusions found from the fourth chapter of work presented
here include:
1. Differential left ventricular response to epinephrine and
immobilization stressors in males versus females
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2. Similar left ventricular responses to epinephrine and immobilization
stressors were seen between males and menopausal females as
compared to age-matched cycling females
3. A drastic reappearance of intrinsic cardiac adrenergic cells were
observed and quantified in the menopausal left ventricular and
apical regions of the heart
The differential responses to stressors in combination with the pattern of
intrinsic adrenergic myocardium could provide useful information for the clinical
syndrome known as takotsubo cardiomyopathy. The creation of a mouse model
for this stress induced cardiomyopathy yields a powerful tool for understanding
the currently undefined pathophysiology. Much work has been conducted
regarding the design of an animal model, with little understanding of the
mechanisms driving this syndrome (Shao et al., 2013a; Shao et al., 2013b).
The modes of stress induction in the mouse model presented here, in
addition to menopausal induction, provide a scenario quite similar to the human
condition. However, a potential pitfall in utilizing the mouse as a surrogate for the
human cardiovascular system is the over stimulated nature of the mouse in a
basal state. The conscious mouse heart rate ranges from 500-650 beats per
minute were as the average human heart rate is 60-100 beats per minute. The
mouse is already in a “stressed” state and external stimuli (i.e. epinephrine and
or restraint) may not have the complete desired outcome. For this reason the
use of larger animal models that are more akin to human cardiovascular function,
such as rabbits, dogs, or cats, may be a suitable alternative to the use of rodents.
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The mouse model utilized here, Pnmt+/Cre ROSA26+/βgal, provided the
opportunity to investigate the intrinsic adrenergic myocardium over time and in
response to menopausal status. However, the LacZ staining observed here is a
historical representation of cells that are capable of producing stress hormones.
Within this study we have not measured the production of epinephrine or
norepinephrine in the heart in response to menopause or stress. A potential
experiment to test the levels of NE/EPI produced would involve culturing the
area(s) most heavily stained (i.e. the left ventricle and atrium) in the aged and
menopausal hearts as compared to controls. While the use of restraint stress
would not be feasible, provocation with isoproterenol could induce increased
beating activity in the cultured myocytes and allow for quantification of the NE
and EPI that is being produced in response to stres. While these experiments
could be informative, they would require a new cohort of mice and reproduction
of the colony.
Alternatively, the current samples available from the study performed here
can be sectioned and stained directly for norepinephrine, epinephrine or other
markers such as Dbh and Pnmt. While quantification is certainly a challenge with
immunofluorescence, differences can be readily observed, especially if the
intensity is electronically quantified using 3D software such as Volocity® (Perkin
Elmer). By employing this method both functional data, via echocardiography,
and biochemical depiction of the levels of adrenergic hormones present in the
areas that stain heavily with LacZ.
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The work performed here demonstrates the importance of adrenergic
hormones in both the developing cardiovascular system as well as the adult
heart. Additionally, this work provides a unique perspective on the effect
adrenergic hormones have on cardiovascular function, heart failure, and sudden
cardiac death. These adult cardiac disease states are often capable of
prevention through manipulation of life style, congenital malformations however,
presents at a stage so early in the pregnancy that most women do not realize
they are even pregnant and have the ability to alter the course of gestation.
Surgical intervention is commonly the only treatment option available to correct
these congenital heart defects. Thus understanding the typical embryogenesis
and organogenesis patterns and the downstream implications these hormones
have is of critical importance to developing new treatment options and potentially
prevention of congenital heart disease.
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